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Abstract 
Introduction 
In this study, we identified the association of Vitamin D with orthodontic tooth movement 
and the impact of Vitamin D 1,25OHD and 25OHD forms on osteoblast function.   
Materials and Methods 
This study is comprised of two parts; a clinical and a laboratory part. In part I, saliva sam-
ples were collected from orthodontic patients each month for the first six months of orthodontic 
treatment along with casts at the beginning and the end of the study period. The samples were 
measured for Vitamin D binding protein (VitDBP) and alkaline phosphatase (ALP) and correlated 
with clinical tooth movement using absolute change in irregularity index (II). In part II, osteoblasts 
were collected from the calvaria of 3-5 day old healthy wild-type mice and cultured with differing 
concentrations of 1,25OHD (1, 10 and 100nmol) and 25OHD (100, 200, 400 nmol). ALP, OPG 
and RANKL were measured as outcomes of Vitamin D treatment of osteoblasts. Intracellular sig-
naling in response to Vitamin D was assessed by identifying the phosphorylation of ERK 1/2, p38 
and NLK in primary osteoblasts.  
Results 
Measurement of salivary Vitamin D binding protein (VitDBP) showed that both low (<2.75 
ng/ml) and high (>6.48 ng/ml) logVitDBP were associated with reduced tooth movement. There 
was no significant correlation between ALP levels and orthodontic treatment. Significant seasonal 
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changes in VitDBP using a two-season year model were found with lower levels noticed in the 
summer (Mar-Sept) than in the winter (Oct-Feb) at p<0.05.  
A decrease in OPG production with higher concentrations of 1,25OHD and 25OHD with 
a corresponding increase in RANKL levels in primary osteoblast cultures was found. Similar to 
the clinical findings, ALP levels were not significantly affected by increasing concentrations of 
both 1,25OHD and 25OHD. The ERK 1/2 showed upregulation in response to treatment with 
1,25OHD and a downregulation in response to treatment with 25OHD concentrations. Meanwhile,  
p38 and NLK were affected by 1,25OHD and not by 25OHD. 
Conclusions 
 Clinical outcomes of orthodontic treatment are associated with a range of optimal Vitamin 
D binding protein (VitDBP) as detected in saliva. Different forms of Vitamin D affect osteoblast 
response and signaling differently.    
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Part I: A Longitudinal Assessment of the Link between Vitamin D Binding Protein and  
Alkaline Phosphatase with Orthodontic Tooth Movement 
 
Introduction 
  The goal of orthodontic treatment is to move the teeth and dentoalveolar structures into 
more a harmonious position, restore alignment, and reestablish health and function of the dentition. 
The success of orthodontic tooth movement is due to multiple mechanical, skeletal and biological 
factors that regulate the bone turnover and other periodontal tissues. Vitamin D plays a major role 
in bone biology. Vitamin D deficiency is an etiological factor in several bone turnover diseases 
such as rickets and osteomalacia. Many other pathologies including, but not limited to, heart dis-
ease, hypertension, diabetes, several malignant diseases as well as autoimmune disorders are also 
being linked to reduced levels or absence of Vitamin D  (El-Khoury, et al., 2011).  While many 
studies have focused on the association between orthodontic tooth movement and vitamin D levels, 
there are still numerous gaps in knowledge (Bartzela, et al., 2009) (Collins, et al., 1988) (Huang, 
et al., 2014) (Kawakami, et al., 2004) (Shetty, et al., 2015). These include an optimal range of 
vitamin D levels in individuals undergoing orthodontic treatment and how different forms of vita-
min D control the bone turnover during this process. Our study is designed to address these two 
issues using a combination of in vivo and in vitro approaches.  
Orthodontic Tooth Movement 
  Teeth are moved through the bone by mechanical forces applied to the teeth. Orthodontic 
tooth movement differs from physiological migration of teeth in the alveolar socket as it is a forced 
displacement of teeth in a new position. This process requires the actions of two main types of 
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cells in bone; osteoblasts and osteoclasts. Osteoblasts are derived from a mesenchymal stem cell 
line whereas; osteoclasts are derived from a monocyte/macrophage line. Osteoblasts, once encased 
in mineralize tissue, become osteocytes which are considered terminally differentiated osteoblasts. 
Their main function is to maintain bone. (Huang, et al., 2014). The balance between the actions of 
these two cell types allows for bone to be resorbed in the direction where the tooth is to move and 
for it to be built in the area where it has vacated.  
  While it is clear that tooth migration in response to orthodontic forces requiring a coupling 
between the osteoblastic bone apposition and osteoclastic bone resorption, the exact mechanism 
of orthodontic treatment is still not fully understood after more than 100 years of studies. There 
are several theories regarding how orthodontic tooth movement (OTM) happens and how the bone 
responds. The most commonly accepted theory of tooth movement is the pressure-tension theory 
presented by Sandstedt in 1904, and further described by Oppenheim in 1911 and Schwarz in 1932. 
(Meikle, 2006). This theory describes the creation of a pressure (compression) side and a tension 
side during tooth movement. The force is applied at the tension side and forces the tooth into the 
pressure side. The rate-limiting step is known to be the bone resorption at the compression side 
while bone is formed at the pressure side. (Huang, et al., 2014). The other common theories are 
the bone-bending and piezoelectric theories. The bone bending theory was introduced in the 1880s 
by Kingsly and Farrar. According to this theory, when a force is applied, the bone “bends” into a 
concave (negative) and convex (positive) surface and the tooth moves due to piezoelectricity  
(Asiry, 2018) (Proffit, et al., 2000). None of these theories sufficiently explain the biology of bone 
response underlying orthodontic tooth movement especially in multi-rooted teeth where pressure-
tension distinction and bending concepts become complicated. Another limitation of these theories 
is their biological relevance where the concepts are not fully supported by tissue responses. 
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  Mechanically the three phases of tooth movement during orthodontic treatment have been 
described as; initial, lag and post-lag (progressive) phases (Burstone, 1962). The initial phase is 
where the force displaces the teeth during the first 1-3 days. The second phase (the lag phase), is 
where no tooth movement occurs which usually takes 2-10 weeks. The third phase (the post-lag 
phase) is where the progressive tooth movement occurs (Burstone, 1962) (Proffit, et al., 2000) 
(Asiry, 2018). These stages of orthodontic tooth movement have been shown in humans and ani-
mal models. It is however, unclear how the biological factors regulate the response to orthodontic 
tooth movement. In addition, the wide time span of especially the lag phase suggests that ortho-
dontic treatment heavily depends on individual response by the patient especially during the initial 
stages of tooth movement. It is also not known what biological mechanisms determine how long 
the subsequent lag phases and progressive phases after the initial stages. Several gaps in knowledge 
exist in understanding the biology and factors regulating the complex orthodontic migration of the 
teeth in alveolar bone and stability of the outcomes 
Vitamin D and Orthodontic Tooth Movement  
Vitamin D is a fat-soluble molecule with a direct effect on mineral ion homeostasis. It 
regulates calcium absorption and the balance between osteoblasts and osteoclasts. It has also been 
shown to regulate osteoblastic differentiation (Kawakami, et al., 2004). Vitamin D correlates with 
parathyroid hormone, calcium and bone health parameters such as bone mineral density, C-termi-
nal polypeptide, bone specific alkaline phosphatase, osteocalcin, and several other key factors that 
play a role in bone turnover (Tsuprykova, et al., 2017).  
  Vitamin D metabolism involves two main types of pre-vitamin D; D2 (ergocalciferol,) and 
D3 (cholecalciferol). Ergocalciferol (VitD2 as it will be referred to) is mainly ingested by the diet, 
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in the form of fortified foods and supplements. Most fortified foods have the D2 form with the 
exception of fatty fish which have the D3 compound (Tsuprykova, et al., 2017). Cholecalciferol 
(referred to as VitD3) is the only vitamin D isoform produced by the mammalian body in response 
to sun exposure. (van den Ouweland, et al., 2013) (Tsuprykova, et al., 2017). After ingestion of 
production both VitD2 and VitD3 are transported to the liver to become hydroxylated into 25OHD2 
and 25OHD3, respectively. These two hydroxylated forms of Vitamin D are collectively referred 
as 25OHD. After the hydroxylation process in the liver, 25-hydroxyvitamin D (25OHD) becomes 
the major circulating form of vitamin D with a half-life of 2-3 weeks. (Holick, et al., 2008) (van 
der Meijen, et al., 2014).  
The active hormonal form of vitamin D in the human body is 1,25 dihydroxycholecalcif-
erols with two hydroxylation sites. 1,25OHD regulates bone deposition and PTH release through 
calcium and phosphate serum absorption and reabsorption in the intestines and kidneys, respec-
tively (Bartzela, et al., 2009). It may also have an effect on the immune system by promoting 
immunosuppression (Bartzela, et al., 2009). 1,25OHD regulates its own metabolism by mediating 
the 24-hydroxylase activity which leads to its degradation (van Driel, et al., 2004).  1,25OHD is 
not a good indicator of circulating vitamin D because its half-life is 4-6 hours and the circulating 
amount is a thousand-fold less than 25(OH)D. Also, as the level of circulating 1,25OHD decreases 
an imbalance in the calcium levels is observed, increasing the production of PTH, which in turn, 
increases the renal levels of 1,25(OH)D (Holick, et al., 2008) (van der Meijen, et al., 2014). 
1,25OHD also has an important and direct role in the genomic signaling of chondrocytes and os-
teoblasts on CYP27B1 which is a gene that provides instructions for making an enzyme called 1α-
hydroxylase that carries out one of the reactions to convert vitamin D to 1,25OHD  (St- Arnaud, 
2008) (van der Meijen, et al., 2014). 1,25OHD induced chondroblasts modulates fibroblast growth 
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factor 23 (FGF23) secretion in osteoblasts, however, it is still unknown what the secreted factor 
is. (St- Arnaud, 2008). It is clear however, that these two forms of vitamin D have distinct roles in 
bone metabolism. How their levels are associated with alveolar bone turnover during orthodontic 
tooth movement and their impact on bone cells is key to understanding the biological basis of 
orthodontic treatment responses in alveolar bone. 
The main enzymes responsible for Vitamin D metabolism in the liver is CYP2R1, 
CYP27A1 and CYP3A4.  CYP27A1 has been shown to only affect the D3 form and not the D2 
form and CYP3A4 does not hydroxylate and only works on drug metabolized Vitamin D. (Dusso, 
et al., 2004) (Anderson, 2017). CYP24A1 works in various tissues to change 25OHD into 24OHD 
and 1,24,25OHD (Rochel, et al., 2017). (van der Meijen, et al., 2014) (Dusso, et al., 2004). Half 
of all CYP24A1-null mice die of hyper-vitaminosis D and hypercalcemia before reaching 3 weeks 
of age (Anderson, 2017). Therefore, it is suggested that CYP24A1 activity is of great importance 
for healing (Anderson, 2017).  From the liver, the 25OHD travels to the kidney where it is trans-
formed into 1,25OHD. In the kidneys CYP27B1 is the only enzyme that acts on the transformation 
of 25OHD to 1,25OHD (Dusso, et al., 2004).  
Vitamin D works on vitamin D receptors in the osteoblasts and other cells to perform its 
functions (Anderson, 2017). Total vitamin D level is regulated by liver functions, kidney diseases, 
pregnancy and genetic backgrounds (Tsuprykova, et al., 2017).  Studies have shown that 25OHD 
may assist in bone building by osteoblasts whereas 1,25OHD may stimulate bone resorption. 
(Eleftheriadis, et al., 2012) Studies done on hemodialysis patients have found that 25OHD sup-
press osteoclast action in cases of inflammation by increasing expression of RANKL (Receptor 
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Activator of Nuclear factor Kappa B Ligand) and inducing the production of OPG (osteopro-
tegerin) (Eleftheriadis, et al., 2012). 1,25OHD induces RANKL activity in immature osteoblasts 
but not in mature osteoblasts (Anderson, 2017).  
  Although there is no consensus of the “normal” serum vitamin D levels in humans, the 
agreement in in the range of >30ng/ml (or >75nmol/L) or 20-80ng/ml (Holick, et al., 2008) 
(Tsuprykova, et al., 2017). Insufficiency of 25(OH)D is considered in the range of 21-29ng/ml and 
deficiency as <20ng/ml. The WHO had previously considered levels below 20ng/ml as insufficient 
and under 10ng/ml as deficient but due to changes in laboratory reference ranges those levels have 
changed (Rosen, 2011). According to an NHANES study, the mean 25OHD levels were 24ng/ml 
(60nmol/L) among several age groups (Rosen, 2011). Some experts consider no upper limit to 
vitamin D levels that would lead to toxicity while others would consider it above 150-200ng/ml 
based on the study of lifeguards (Holick, et al., 2008).  
  Many factors affect the variation in pre-vitamin D conversion including skin type, type, 
amount and duration of sun exposure, surface area exposed to sun, geographical location, and age 
are some of them (Abboud, et al., 2017). Although sunlight exposure is the main way vitamin D3 
is synthesized in the body, not all sunlight is equal. A Ultraviolet B (UVB) irradiation (wave-
length:280-315) threshold of 20mJ/cm2 is required to induce the transformation of 7-DHC into 
pre-vitamin D3 (Hollis, 2005). For example, in winter (November through February) in Boston 
where the latitude is above 400 (420 N) the daily accumulated UVB solar irradiation from 11:30-
14:20 EST remains below 20mJ/cm2 (Hollis, 2005). Sunscreen and skin color also have a major 
effect on blocking UVB absorption (Hollis, 2005). In areas where cultural norms require more skin 
coverage by clothing the UVB absorption becomes even less. A very high prevalence of vitamin 
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D deficiency has been reported in Saudi Arabia despite having one of the highest numbers of sunny 
days per year (Tuffaha, et al., 2013). In another study testing 60,979 patients from 136 different 
countries found that hypovitaminosis D is significantly higher in Middle Eastern countries (Haq, 
et al., 2016).  
  In order to raise vitamin D levels in the absence of adequate sun exposure, 800-1000 IU 
vitamin D3 is prescribed to patients (Holick, et al., 2008). However, the nutritional labeling value 
in the United States is 400 IU. This level is believed by authors such as Hollis to be inadequate. It 
seems to be an effective dose to raise the 25OHD concentration to 80-200nmol/L in infants only 
but seems to have little to no effect on adults (Hollis, 2005). For vitamin D deficiency, Holick 
recommends 50,000 IU vitamin D2 once a week or every two weeks for 8 weeks to attain a 25OHD 
concentration of 75nmol/L (Holick, et al., 2008).  For every 40IU of vitamin D intake, we see an 
increase of 0.70nmol/L of circulating 25OHD over a 5-month regimen (Hollis, 2005) a greater the 
rise with supplementation is obtained the lower the baseline levels (Rosen, 2011). 
  Circulating vitamin D is found in three forms; 85-90% is bound to VitDBP, 10-15% is 
loosely bound to serum albumin and less than 0.03% is found in an unbound and free form. (Bikle, 
2014). Vitamin D is brought to the liver by the use of Vitamin D Binding Protein (VitDBP). There, 
Vitamin D2 and D3 are metabolized into the 25-OHD2 and 25-OHD3 respectively. (Su, et al., 2014). 
VitDBP has a higher affinity with the 25OHD form and less with the 1,25OHD (10-100-fold lower) 
due to the additional hydroxyl group. If 25OHD concentrations are around 20-80ng/ml and 
1,25OHD levels are 1000-fold lower, then VitDBP levels are estimated around 20-fold higher than 
all vitamin D forms together  (Tsuprykova, et al., 2017). VitDBP is less than 1% saturated normally 
considering that its serum concentration (6.10-6M) is much larger than the concentration of 25OHD 
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(4.10-8M) and that the free concentration of 25OHD is not regulated at a constant level (Bouillon, 
et al., 1977). The most common theory is the free hormone hypothesis, which states that only 
unbound hormones are biologically free to perform their physiologic activities but protein-bound 
hormones are biologically inactive (Yousefzadeh, et al., 2014) 
  Vitamin D Binding Protein (VitDBP) is a polymorphic single-chain serum glycoprotein 
found in many body fluids and organs, including but not limited to, serum, saliva, breast milk, 
cerebrospinal fluid and lungs, kidneys, spleen and placenta (Delanghe, et al., 2015). VitDBP is 
produced by the liver and is responsible for transporting 25OHD and1,25OHD to the cells. It also 
is filtered through the kidneys, particularly the molecular sieve of the glomerular filtration barrier 
and re-uptaken by the megalin/cubulin system in the proximal tubules (Rochel, et al., 2017) 
(Tsuprykova, et al., 2017). Therefore, diseases that affect the liver and kidneys such as, liver cir-
rhosis and chronic kidney diseases affect the levels of VitDBP in the blood (Tsuprykova, et al., 
2017). The main functions of VitDBP are binding, solubilizing and transport of Vitamin D and its 
metabolites. There are over 120 unique racial variants of VitDBP but the most common are 
DBP1F, DBP1S and DBP2 (Delanghe, et al., 2015). Studies have proven that serum VitDBP con-
centrations and 1,25OHD3 levels are positively correlated (Delanghe, et al., 2015).  
  VitDBP is found to vary according to race, age and gender. Differences have been found 
in measuring free 25OHD between races because African Americans were found to have less cir-
culating free 25OHD but stronger bones. They have lower levels of VitDBP resulting in equivalent 
levels of calculated free 25OHD3. (Hong, et al., 2018).  In African Americans, higher levels of 
vitamin D deficiency are noted than in Caucasians. They are also more likely, along with Asians, 
to carry mutations of the GC1F single nucleotide polymorphism (SNP) which has a high affinity 
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for 25OHD and lower VitDBP. Caucasians are more commonly found to have the GC1S SNP, 
which has the opposite affinity. In another study by Bouillon et al. found no racial differences in 
normal serum concentrations of VitDBP between whites from Belgium and blacks from Zaire 
(Bouillon, et al., 1977). 
  Age and gender are also factors that affect VitDBP levels. Vitamin D insufficiency is more 
common in older than younger individuals. VitDBP is negatively correlated with age in females 
rather than males (Yousefzadeh, et al., 2014). Other studies have shown no differences in VitDBP 
levels in aging (Delanghe, et al., 2015).  Women were found to have higher mean VitDBP levels 
than men but no other associations were noticed between VitDBP levels and age, bodyweight, 
BMI, fat mass or fat percentage. (Pop, et al., 2015). They also found that postmenopausal women 
had lower Vit DBP levels than premenopausal. (Pop, et al., 2015) (Nimeri, et al., 2013). In another 
study by Bouillon in 1977, they noticed higher concentrations in women than men in parallel with 
what Pop et al. concluded. (Bouillon, et al., 1977) (Pop, et al., 2015).   
  Certain diseases also affect vitamin D and VitDBP levels. Vitamin D deficiency or insuf-
ficiency is slightly increased in patients with Diabetes with albuminuria which in turn, coincides 
with an increase in urinary VitDBP. (Delanghe, et al., 2015). Vitamin D3 synthesized endoge-
nously was also noted to be different than ingested Vitamin D2. (Haddad, et al., 1993). Plasma 
25OHD levels were found by Zhang et al to be higher in patients with generalized aggressive 
periodontitis than healthy controls. This was also found to be positively correlated with the gingi-
val bleeding index. Initial periodontal therapy was shown to decrease local and systemic levels of 
25OHD. (Zhang, et al., 2014) As for VitDBP levels, they were shown to be increased in salivary 
levels of patients with periodontitis (Wu, et al., 2009). Another interesting finding to note was that 
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serum levels of VitDBP were not affected by several diseases of calcium metabolism (primary 
osteoporosis, primary and secondary hyperparathyroidism, rickets, osteomalacia or vitamin D in-
toxication) but liver and kidney diseases did. (Bouillon, et al., 1977) (Tsuprykova, et al., 2017).  
  There is substantial controversy surrounding how to correctly measure vitamin D.  Between 
25OHD and 1,25OHD, 25OHD is usually considered as the measure of vitamin D status due to its 
longer half-life (10-15 days) compared to 1,25OHD (4-6 hrs.). Another important factor in choos-
ing 25OHD is that circulating levels are 1000 time more than 1,25OHD which is measured in 
picograms as opposed to 25OHD’s nanograms. 1,25OHD has also been noted to be directly influ-
enced by serum calcium, phosphorus and parathyroid hormone more than 25OHD (Su, et al., 
2014). A Vitamin D Standardization Program was established to develop protocols for standard-
izing the existing serum 25(OH)D data from national surveys around the world. This program 
includes participants from several different countries including the US, Belgium, UK, Australia, 
Canada, Germany, Ireland, Mexico and South Korea. They aim toward standardizing the labora-
tory measurement of vitamin D and improving the detection, evaluation and treatment of vitamin 
D deficiency. (https://ods.od.nih.gov/Research/vdsp.aspx#overview)  (Cashman, et al., 2015). 
However, the problem is not only in how to measure 25OHD but some researchers believe we 
should be measure VitDBP and serum albumin as well due to the fact that less than 0.03% of 
25OHD is unbound (Tsuprykova, et al., 2017). The first assays for measuring total 25OHD were 
based on a VitDBP competitive protein binding method; however, this method includes other vit-
amin D metabolites other than only 25OHD which are usually inactive. (Jassil, et al., 2017)  
  Several methods of measuring vitamin D are now available. The methods are divided into 
two main groups; immunochemical and chromatographic/physical. Radioactive, enzymatic or 
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chemiluminescence detection fall under the first group, whereas HPLC and LC-MS/MS fall under 
the second. (van den Ouweland, et al., 2013) (Enko, et al., 2014). Traditionally, radio-immune 
assays, high-performance liquid chromatography (HPLC) with UV detection and radioimmunoas-
say have been used routinely, however, due to the high demand for superior sensitivity and speci-
ficity, new methods are being used. Liquid Chromatography coupled with electrospray ionization 
(ESI) or atmospheric pressure chemical ionization (APCI)-mass spectrometry (MS) are now the 
more popular options (Higashi, et al., 2008). LC-MS is used for the direct measurement of total 
25OHD (Holick, et al., 2008). It can distinguish between 25(OH)D3 and 25(OH)D2, and therefore 
can report individual and total levels of 25(OH)D (El-Khoury, et al., 2011).  However, Su et al 
found that though most manufacturers claim that their LC/MS/MS assays equally measure D2 and 
D2, Vitamin D Binding assays overestimate 25OHD3 by 10.8% and underestimate 25OHD2 by 
38.4% which is problematic in that US prescription supplements of Vitamin D are usually the D2 
form (Su, et al., 2014) One of the issues with LC-MS methods is that they can show up to 15% 
higher results than protein binding assays and some immunoassays (El-Khoury, et al., 2011). An-
other problem of the LC-MS method is that the vitamin D molecule is lipophilic and therefore 
difficult to ionize due to its lack of easily chargeable groups (El-Khoury, et al., 2011). .  
  A Cookson-type reagent has been used with some success in a study by Higashi (Higashi, 
et al., 2008). Knox and Højskov also reported some progress with a protein precipitation extraction 
(El-Khoury, et al., 2011). Use of human breast milk and dried blood spots have also been reported 
to be used for LC-TMS analysis of vitamin D levels (El-Khoury, et al., 2011). The National Insti-
tute of Standards and Technology and the Centers for Disease Control and Prevention have chosen 
LC/MS/MS as the reference method for measuring 25OHD however, there is no reference method 
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when measuring VitDBP although most experts use polyclonal antibody based immunoassays. 
(Su, et al., 2014) (Malmstoem, et al., 2017)  
  A study by Higashi et al. in 2008 developed a method to accurately measure the 25(OH)D 
levels in 1.0ml sample of saliva after derivatization with 4-phenyl-1-1,2,4-triazolin-3,5-dione 
(PTAD). (Higashi, et al., 2008)  This definitely carries the appeal of being noninvasive compared 
to serum measurement which is considered the gold standard. There is a proven correlation be-
tween the levels of vitamin D in saliva and serum (Higashi, et al., 2008). However, the main dis-
advantage of using saliva is the low analyte concentration (Higashi, et al., 2008). They also noted 
that the saliva samples were stable to up to 3 freeze/thaw cycles and that it was possible to store 
the saliva at -20 degrees Celsius for up to four months without loss of 25(OH)D3 (Higashi, et al., 
2008). In a later study by the same author in 2010, they found that there was no significant effect 
of storage conditions such as light exposure, room temperature storage for two weeks and 10 
freeze/thaw cycles on the measured values (Higashi, et al., 2010). The 25(OH)D3 levels in saliva 
were found to be significantly lower (one thousandth) than that of serum. However, a good corre-
lation was also observed between them, proving that there is a reliable ratio between the 25(OH)D3 
levels in saliva and serum (Higashi, et al., 2008) (Higashi, et al., 2010). Therefore, saliva assays 
can be used for the assessment of vitamin D status of patients. This method proved to be specific, 
accurate and reproducible and can be used successfully in application to clinical studies (Higashi, 
et al., 2008).  
  When measuring VitDBP, immunonephelometry has been used with both monoclonal and 
polyclonal antibodies. This manages to assay all three major electrophoretic variants (Gc2, Gc1s 
and Gc1f). (Jassil, et al., 2017). Most studies use enzyme linked immunosorbent assay (ELISA) to 
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measure VitDBP, which uses 2 monoclonal antibodies in a sandwich format. This may be different 
when compared to methods using polyclonal antibodies. (Jassil, et al., 2017). Polyclonal tech-
niques have shown no significant racial differences when measuring VitDBP. (Denburg, et al., 
2016). According to a study by Hong et al in 2018, Vitamin DBP is a valid measure to determine 
free 25OH vitamin D3 status in conjunction with total 25OHD3. (Hong, et al., 2018). Luminex, 
which is a bead based immunoassay that uses dye defined beads coated with anti-analyte antibod-
ies and is usually used for multiplexing to measure several analytes for each sample,  has also been 
used successfully in measuring VitDBP levels (Dudal, et al., 2014).  
Alkaline Phosphatase 
  Alkaline phosphatase (ALP) is a glycoprotein produced by fibroblasts, osteoblasts and os-
teoclasts. It plays a role in mineral formation of hard tissue structures like bone and cementum as 
first studied by Robinson in 1923 (Robison, et al., 1924) (Farahani, et al., 2015). It is known to be 
a biological marker of osteoblastic activity during bone deposition (Farahani, et al., 2015) (Rodan, 
1992). Normal levels in human osteoblasts were found by Corrado et al to be 29.85 ± 4.93. 
(Corrado, et al., 2013).  Several studies have measured ALP levels in GCF (gingival crevicular 
fluid) during tooth movement to better understand the biology behind tooth movement. In a study 
by Perinetti in 2011, it was found that ALP levels in GCF can be used as a non-invasive clinical 
biomarker for measuring the skeletal maturation of orthodontic patients. It was compared to CVM 
(cervical vertebral maturation) and found to be significantly related (Perinetti, et al., 2011).  Fara-
hani et al, noticed that the peak ALP levels during orthodontic tooth movement were noticed at 
day 14 and 28 (Farahani, et al., 2015).  ALP activity values were also noted as being higher in the 
tension rather than compression sides of tooth movement, which may be explained by the greater 
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bone deposition at that side but were more pronounced after tooth movement had ceased. 
(Farahani, et al., 2015) (Flórez-Moreno, et al., 2013).  
  ALP has been studied in saliva as a biomarker of bone resorption occurring with periodon-
tal disease. Patel et al found that in periodontal diseases, the levels of ALP increased as the disease 
progressed from gingivitis to periodontitis at a statistically significant level p<0.001 (Patel, et al., 
2016).  They also noted the salivary ALP levels to be 20.70±7.18 U/L in healthy periodontium, 
33.06±5.49 U/L in gingivitis and 49.62±16.46 U/L in periodontitis (Patel, et al., 2016). However, 
in another study by Sophia et al, they had higher levels comparing healthy and periodontally dis-
eased post-menopausal women with healthy levels at 37.26±9,92 and periodontitis 70.43±4.36 
(Sophia, et al., 2017).  In a study by Jazaeri et al, mean salivary ALP activity levels were found at 
5.04±1.866 U/dl measured by the Kinetic method to convert 4-nitrophenyl phosphate to 4-nitro-
phenol (Jazaeri, et al., 2015). Limited studies focused on salivary ALP levels have also been stud-
ied in regards to orthodontic tooth movement by Flórez-Moreno et al where the levels appeared to 
consistent and show no differences between time points (Flórez-Moreno, et al., 2013). Yet, a clear 
understanding of ALP levels in saliva is required to understand its biological value as a factor and 
marker of orthodontic tooth movement. 
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Hypothesis 
Null Hypothesis: (H0): There is no correlation between Vitamin D Binding Protein and Alkaline 
phosphatase levels and the rate of orthodontic tooth movement. 
Hypothesis: (H1): Vitamin D binding protein and Alkaline phosphatase levels are correlated with 
the rate of orthodontic tooth movement 
 
Aims 
Overall Aim 
  The aim of this study was to measure the correlation between salivary vitamin D binding 
protein and alkaline phosphatase levels and the rate of tooth movement with orthodontic treatment 
in the orthodontic patient population.  
Specific Aims 
1. To determine if baseline salivary level of VitDBP and ALP levels changes the rate of or-
thodontic tooth movement and identify the impact of confounding factors such as the sea-
sonal effects on VitDBP levels 
2. To measure the change in VitDBP and ALP levels in response to orthodontic treatment 
3. To determine the correlation between salivary VitDBP and ALP levels during orthodontic 
tooth movement 
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Materials and Methods 
A total of 127 patients were recruited from the Department of Orthodontics and Orthofacial 
Orthopedics at the Henry M Goldman School of Dental Medicine at Boston University after IRB 
approval. All subjects were provided with written and oral consent to be included into the study. 
Participants with any medical conditions that might affect bone metabolism or who were taking 
any vitamin D supplements were excluded from the study. As part of the orthodontic treatment 
standards, patients with active periodontal disease do not start orthodontic treatment until their 
disease is under control; therefore, we excluded patients with signs of periodontal disease from in 
this study.  
The saliva samples were collected at each visit for 6 consecutive, monthly visits during the 
leveling and aligning stage of orthodontic treatment. Impressions were taken before orthodontic 
treatment was started as part of the orthodontic treatment records. A second set of alginate impres-
sions were taken at the end of the study period.  Whole saliva was collected in 15ml polypropylene 
Falcon tubes at each appointment and immediately placed in a -800c freezer at Boston University. 
Once collection was completed, the samples were transported in dry ice to the Forsyth Institute for 
analysis. 
  Subjects were enrolled in the study between April 2017 and March 2018 from the patients 
seeking orthodontic treatment at the Henry M Goldman School of Dental Medicine at Boston Uni-
versity. The patients were asked if they had any medical conditions or were taking any medications 
including vitamin supplements and were not included if they did. The treatment plans varied be-
tween extraction and non-extraction cases and between traditional braces, clear aligner therapy 
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and others such as expanders or headgears. The treatment was completed by the orthodontic resi-
dents at the university under the supervision of the faculty. The initial samples were taken at the 
treatment planning appointment and then consecutively after treatment had started. Alginate im-
pressions were taken at the 7th and final appointment after 6 months of treatment. The casts were 
then scanned along with the initial models to be measured for the tooth movement.  
Measurement of Irregularity and Crowding 
  Little’s Irregularity Index (II) is an orthodontic treatment index which was developed by 
Robert Little in 1975. It measures the distance between contact points of the mandibular canine to 
canine region regardless of the direction of the distance. (Little, 1975) It is a useful tool in deter-
mining the amount of incisor irregularity but does not measure crowding only in terms of lack of 
space. It is considered faster and easier than other indices.  
  Initial and final casts were scanned using the Ortho Insight 3D from Motion View LLC., 
(Chattanooga, Tennessee) scanner and software. Teeth were identified using the software and the 
mesial and distal contact points corrected manually. The irregularity index was then measured 
using the software for each before and after cast as well as the absolute difference between them 
for statistical analysis.  
Processing and Analysis of Saliva 
  Saliva samples were thawed and centrifuged at 12,000 rpm for 10 minutes and the super-
natants were aliquoted into 2ml Eppendorf tubes. The samples were then measured for ALP using 
Abcam Alkaline Phosphatase Assay kit (Colorimetric) (ab83369) according to manufacturer’s in-
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structions (protocol in appendix below). Optical density (OD) of the products at 405 nm was meas-
ured by spectrophotometry. Enzyme activity was calculated as the OD of the reaction product 
multiplied by the reaction volume and normalized to the reaction time and to the total protein. For 
the VitDBP, the kit used was Human Circulating Cancer Biomarker Magnetic Bead Panel 2 (Cat. 
#HCCBP2MAG-58K) from EMD Millipore. The samples were run on the Luminex® 200™. All 
ALP samples were run using the same kit and the VitDBP using kits from the same batch at the 
same time to reduce possible variation from external factors. 
Statistical Analysis 
  Statistical analysis was performed using SAS 9.4 software with mixed and linear regression 
models. Descriptive statistics were summarized using mean and standard deviation for continuous 
variables and frequency for categorical variables, respectively. Data were thoroughly checked for 
potential data entry errors and outliers. Mixed linear regression models and traditional linear re-
gression models were used to assess the relationship between VitDBP and season and between 
baseline VitDBP and absolute difference in tooth irregularity. 
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Results 
 A total of 127 patients were recruited for the study. 84 patients completed the study but 73 
were included in the final analysis due to multiple missing samples and casts.  Of the 6 timepoints, 
only 4 were measured including the first and last sample in order to have consistency in the number 
of acceptable samples for each participant. Of the final 73 subjects, 43 were female and 30 males, 
yielding a female/male ratio of 1.38. The age ranged from 8 to 63 years old with a mean age of 
21.5±11.07. In the child group (<18 years old) the mean age was 13.2 and in the adults (>18 years 
old) the mean age was 30.2. The adult (n=36) to child (n=37) ratio in the study was 0.97. Angle 
classification of subjects was Class I (n=48), Class II including both division 1 and 2 (n=18) and 
Class III (n=7) which was consistent with the average normal ratios seen in an orthodontic clinic. 
The treatment plans were extraction (n=16), non-extraction (n=39), clear aligners (n=10) and oth-
ers (n=8). The “other” category included were considered any treatment plan that did not involve 
the above mentioned, such as expansion or splint therapy. Racial ethnicity was self-reported and 
included; African Americans (n=27), Asians (n=6), Caucasians (n=17) and Hispanics (n=23).  
In our analysis, we examined the patterns of change in VitDBP and ALP levels across four 
time points. Subjects were grouped into one of four groups according to whether their VitDBP or 
ALP levels changed from quartile to quartile over different time points into changed (fluctuating), 
monotone increasing, monotone decreasing and no change. Although no statistically significant 
group differences in the mean absolute differences in II were observed, subsequent analysis re-
vealed that if comparing subjects with any changing patterns in VitDBP (i.e. monotone increasing, 
monotone decreasing or fluctuating) to those in the no change group, we observed that the no 
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change VitDBP group showed overall smaller mean absolute differences in II than those in the 
changed groups. 
The tables below show the demographic data for the enrolled subjects according to the 
change in quartiles of VitDBP over time points as well as the average logVitDBP, ALP and ALP 
activity measures for all four time points. 
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Variables Overall Change No Change P-value 
Age 21.63±11.07 21.95±11.71 20.67±11.71 0.6735 
Gender     
Male 30(41.1) 23(31.51) 7(9.59) 1 
Female 43(58.9) 32(43.84) 11(15.07) 
Classification     
Class I 48(65.75) 35(47.95) 13(17.81) 0.3438 
Class II div-1/2 18(24.66) 13(17.81) 5(6.85) 
Class III 7(9.59) 7(9.59) 0(0) 
Treatment Plan     
Extraction 16(21.92) 11(15.07) 5(6.85) 0.9295 
Non Extraction 39(53.42) 30(41.1) 9(12.33) 
Clear Aligners 10(13.7) 8(10.96) 2(2.74) 
Other 8(10.96) 6(8.22) 2(2.74) 
Race     
African American 27(36.99) 22(30.14) 5(6.85) 0.5957 
Asian 6(8.22) 5(6.85) 1(1.37) 
Caucasian 17(23.29) 13(17.81) 4(5.48) 
Hispanic 23(31.51) 15(20.55) 8(10.96) 
Table 1: Demographic data for enrolled subjects 
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Variables Time Overall Change No Change 
logVitDBP 1 4.24±2.12 3.91±1.71 5.23±2.86 
2 4.4±2.13 4.13±1.85 5.23±2.73 
3 4.09±1.89 3.75±1.28 5.12±2.9 
4 4.27±2.1 3.97±1.76 5.18±2.77 
ALP 1 8.96±9.41 7.38±7.27 13.8±13.21 
2 10.13±9.5 10.08±8.91 10.27±11.39 
3 8.52±7.27 7.29±5.05 12.21±11.05 
4 10.08±7.58 9.75±7.05 11.11±9.18 
ALP Activity 1 1.87±1.96 1.54±1.51 2.87±2.75 
2 2.11±1.98 2.1±1.86 2.14±2.37 
3 1.77±1.51 1.52±1.05 2.54±2.3 
4 2.1±1.58 2.03±1.47 2.31±1.91 
Table 2: log VitDBP and ALP averages over time points for all subjects 
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 Looking at only baseline logVitDBP, it was not significantly related with the absolute 
change in tooth II at p=0.0748. We hypothesized that subjects with a normal range of VitDBP 
show higher tooth movement levels, measured by the absolute difference in II. In this study, we 
ranked the subjects by their VitDBP levels. Subjects with VitDBP in the middle 50% were called 
“normal”, while the others were classified as “extreme”. Table 3 shows that VitDBP in log scale 
was between 2.75 and 6.48ng/ml for the normal range group (middle two quartiles), £ 2.69ng/ml 
for the extremely low subgroup (first quartile) and between 6.59 and 8.42ng/ml for the extremely 
high subgroup(fourth quartile). Our analysis shows that the normal range group (mean= 2.36±0.28) 
had significantly higher mean absolute differences in II (p=0.002) than the extreme group (mean= 
1.22±0.31). The group level ranges for absolute change in II is reported in Table 3 below. Demo-
graphic information by normal vs extreme VitDBP groups are shown in Table 4.  
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 Normal Extreme 
  Low High 
LogVitDBP 2.75 - 6.48 ng/ml 0 – 2.69 ng/ml 6.59 - 8.42 ng/ml 
Absolute change in II 0.14 – 7.48 mm 0.11 – 5.63 mm 0.07 – 3.32 mm 
Table 3: LogVitDBP and II between normal and extreme ranges 
 
  Normal Extreme 
   Low High 
Age  20.05 ± 11.74 22.78 ± 7.89 23.72 ± 12.39 
Gender Male 15 (20.55) 9 (12.33) 6 (8.22) 
 Female 22 (30.14 9 (12.33) 12 (16.44) 
Race African American 12 (16.44) 8 (10.96) 7 (9.59) 
 Asian 4 (5.48) 0 (0) 2 (2.74) 
 Caucasian 11 (15.07) 2 (2.74) 4 (5.48) 
 Hispanic 10 (13.7) 8 (10.96) 5 (6.85) 
Table 4: Demographic data of subjects in Normal and Extreme groups 
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 In an exploratory analysis, we found that neither ALP concentration nor ALP activity were 
not significantly related to both total ALP concentration area under the curve (p=0.039) and the 
absolute change in ALP between the first and last time points (p=0.0018)  
 A mixed regression model with random intercept was used to assess the seasonal effects 
on VitDBP. A seasonal variable was created. The samples collected between March and Septem-
ber were considered “summer” and those between October and February “winter”. A significant 
seasonal difference in VitDBP was observed (p<0.05). Samples collected in the winter season 
(4.47±0.30) had significantly higher VitDBP than those collected in the summer season (4.24 
±0.30). 
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Discussion 
In this study, we compared the salivary VitDBP and ALP levels of orthodontic patients 
over the first 6 months of orthodontic treatment (leveling and aligning phase) with the absolute 
change in irregularity index measured before and after the 6 month period. The distribution of 
subjects in this study correlates with the average population of patients in the Henry M Goldman 
School of Dental Medicine Orthodontic clinic in terms of age, gender, race, classification and 
treatment plan. We found this sample distribution to be representative of the population studied.    
There is no international standardized level for VitDBP in human saliva or serum. Serum 
levels are usually estimated between 300 and 600 mg/L in healthy subjects (Delanghe, et al., 2015). 
However, there are no studies to our knowledge of VitDBP levels in saliva. Our study showed 
logVitDBP levels between 0 and 8.42 ng/ml. Although previous studies have shown differences 
in vitamin D and VitDBP levels with age, gender and race, our study showed no statistically sig-
nificant effects at p<0.05 (Hong, et al., 2018) (Bouillon, et al., 1977) (Nimeri, et al., 2013) (Pop, 
et al., 2015). Considering the type of vitamin D measured, between 25OHD, 1,25OHD and 
VitDBP, VitDBP was deemed the most appropriate due to its higher concentration in the body and 
its expression in saliva. 25OHD was another viable option, however, considering that less than 
0.03% of 25OHD is unbound and free, the commercially available kits and the controversy in 
measurement, we decided that VitDBP would be a more appropriate measurement. According to 
a study by Hong et al in 2018, Vitamin DBP is a valid measure to determine free 25OH vitamin 
D3 status in conjunction with total 25OHD3 (Hong, et al., 2018).   
When considering the technique to measure vitamin D in this study, we looked into several 
methods. The National Institute of Standards and Technology and the Centers for Disease Control 
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and Prevention have chosen LC/MS/MS as the reference method for measuring 25OHD however, 
there is no reference method when measuring VitDBP although most experts use polyclonal anti-
body based immunoassays. (Su, et al., 2014) (Malmstoem, et al., 2017). The most feasible one was 
the Luminex kit was used due to ease, accuracy of measurements and availability of the needed 
equipment at the Forsyth institute. This kit allowed us to reproducibly measure the VitDBP levels 
in collected saliva.  
ALP is a biomarker of osteoblastic activity that reflects tissue responses during orthodontic 
tooth movement (Farahani et al). There is no consensus on the normal salivary ALP levels, how-
ever,  several studies have shown means of  20.70±7.18 U/L in healthy patients in a study by  Patel 
et al and 37.26±9,92  by Sophia et al (Patel, et al., 2016) (Sophia, et al., 2017). ALP activity was 
measured using the kinetic method by Jazaeri et al to be 5.04±1.866 U/dl (Jazaeri, et al., 2015). In 
our study, we found the mean ALP concentration levels to be 9.33±8.47 pg/ml and ALP activity 
1.94±1.76 uM/min/mg protein.  ALP concentration and activity were not significantly correlated 
with absolute change in Irregularity Index over the total 6-month period. This correlates with what 
was found by Flórez-Moreno et al where ALP levels appeared to consistent and show no differ-
ences between time points in orthodontic patients (Flórez-Moreno, et al., 2013).  
When dividing the subjects into whether their VitDBP or ALP levels fluctuated between 
quartiles over time points or remained in the same quartile, there were significant differences. We 
considered those that changed quartiles, whether increasing, decreasing or fluctuating to be a 
“changed” group and those that did not as a “no change group”. The changed group had higher 
mean absolute differences in irregularity index. This shows that fluctuation in VitDBP levels may 
have an impact of the rate of tooth movement. Further study is needed in this area to determine the 
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exact pathway of this change. However, with ALP levels, there was no significant differences 
between the changed and no change groups.  
We hypothesized that subjects with a normal range of VitDBP show higher tooth move-
ment levels, measured by the absolute difference in II. In this study, we ranked the subjects by 
their VitDBP levels. Subjects with VitDBP in the middle 50% were called “normal”, while the 
others were classified as “extreme”. VitDBP in log scale was between 2.75 and 6.48ng/ml for the 
normal range group, between 0 and 2.69ng/ml for the extremely low subgroup and between 6.59 
and 8.42ng/ml for the extremely high subgroup. Our analysis shows that the normal range group 
(mean= 2.36±0.28 ng/ml) had significantly higher mean absolute differences in II (p=0.002) than 
the extreme group (mean= 1.22±0.31 ng/ml).Vitamin D has been studied in regards to accelerating 
tooth movement in several animal studies (Nimeri, et al., 2013) (Bartzela, et al., 2009) 
(Diravidamani K., 2012). Local injections of 1,25OHD in cats showed a 60% increase in tooth 
movement (Collins, et al., 1988). Bone regeneration was also enhanced after local and systemic 
vitamin D supplementation in dogs according to Hong et al. (Hong, et al., 2018). Accelerated tooth 
movement in rats was found with Vitamin D injections in the studies of Kale (Kale, et al., 2004), 
Kawakami (Kawakami, et al., 2004), as well as increased number of osteoclasts and osteoblasts 
(Kawakami, et al., 2004). In a clinical, split mouth study by Shetty et al, there was a decreased 
amount of tooth movement in humans after injection with vitamin D3 (Shetty, et al., 2015). There 
have also been several cases of systemic reviews that have included vitamin D as a stimulant for 
tooth movement (Nimeri, et al., 2013) (Bartzela, et al., 2009). Vitamin D has been shown to be a 
stabilizing agent in orthodontic tooth movement. (Diravidamani K., 2012).  As well as a seemingly 
29 
 
opposing view in a study by Tyrovola and Suda (Tyrolvola, et al., 2008) (Suda, et al., 2003). Alt-
hough it seems to show that it may not speed up tooth movement, they have shown that at physi-
ologic levels of Vitamin D, the counter effects do not present themselves (Suda, et al., 2003) . 
Previous studies have shown that there is significant seasonal fluctuation in 25OHD 
(Oleröd , et al., 2017) and 1,25OHD levels (Darling et al). During winter, both free and calculated 
serum 25OHD levels were found to be higher than in the summer (0.020 ± 0.005% vs 0.019 ± 
0.004%; P = 0.007 according to Oleröd et al (Oleröd , et al., 2017). However, they noticed no 
significant differences in VitDBP or albumin levels. In our study we noticed a p<0.05 significant 
difference in salivary VitDBP levels when considering a two-season year model. We found that 
during the “winter” season defined as October to February, salivary logVitDBP levels were found 
to be higher than in the “summer” season (March to September). This correlates with changes 
noted in 25OHD and 1,25OHD but not previous studies of VitDBP.  There may be a relation 
between the binding capacity of VitDBP and the circulating 25OHD levels and its metabolites. 
Further studies are needed in order to determine the seasonal effects on VitDBP levels and its ac-
tivity on 25OHD and 1,25OHD levels.   
 
 
 
 
 
30 
 
Part II: Impact of Vitamin D (1,25OHD and 25OHD) on Osteoblast Function  
 
Introduction 
Bone is made up of three main cell types; osteoblasts that form bone, osteocytes that main-
tain bone and osteoclasts that resorb bone. Osteoblasts come from mesenchymal stem cells, which 
are the precursors of four cell lines; adipogenic, myogenic, osteochondral progenitor and pre-os-
teoblast lines (Rutkovskiy, et al., 2016). In order for the pre-osteoblastic line to occur the Runx/Os-
terix system must be activated. This activation is regulated by the presence of MMP13. 
(Rutkovskiy, et al., 2016) 
The pre-osteoblastic cells become fully mature osteoblasts by transitioning into several 
stages. These stages have been divided by Rutkovskiy et al in a 2016 article into three stages 
(Rutkovskiy, et al., 2016). Stage 1 is when the osteoblasts continue to proliferate and secrete fi-
bronectin, collagen type 1, TGF beta receptors and osteopontin. Stage 2 occurs when the cells exit 
the cell cycle and start to differentiate and the extracellular matrix begins to maturate. Alkaline 
phosphatase and collagen type I are secreted during this stage. The 3rd stage, which occurs before 
osteoblasts are fully matured, is characterized by mineralization of the matrix with an organic 
scaffold of mineral deposition of osteocalcin, osteopontin, bone sialoprotein and calcium phos-
phate. Mature osteoblasts are then either surrounded by mineralized tissue and become osteocytes 
or if nearer to the surface become bone lining cells. The late stages of maturation are controlled by 
the Wnt/Notch pathway and bone morphogenic proteins which have an effect on the Runx2 and 
Osterix expression to encourage the differentiation of new osteoblasts (Rutkovskiy, et al., 2016).  
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The osteoblasts are counteracted by osteoclasts. Osteoclasts come from monocyte/macro-
phage cell lineage and fuse together to form multinucleated cells. These osteoclasts are in charge 
of resorbing the formed bone using tartrate-resistant acid phosphatase (TRAP), matrix metallopro-
teinases (MMPs) and cathepsin K, providing a balance to the osteoblasts building bone (Shaw, et 
al., 2016).  
The main pathway osteoblasts and osteoclasts communicate is the OPG/RANKL (osteo-
protegerin/ receptor activator of nuclear factor kappa B ligand) pathway. This ensures a balance 
between both cells giving way to the modeling/remodeling of bone structures.  RANKL, when 
bound to its receptor on the osteoclast determines the differentiation, function and survival  
(Huang, et al., 2014). OPG is a decoy receptor of RANKL and therefore decreases its effectiveness. 
OPG inhibits osteoclast formation and encourages osteoblast action. RANKL is a protein that is 
essential for the development of osteoclasts as well as T cells and dendritic cells (Rutkovskiy, et 
al., 2016). OPG is decreased and RANKL increased in response to compression, which facilitates 
tooth movement in orthodontic treatment (Huang, et al., 2014). The active form of vitamin D 
(1,25OHD) is a major player in this pathway (Lips, 2006) (St- Arnaud, 2008).  
In the case of inflammation, several processes become disturbed. The system shifts to the 
favor of the osteoclast/bone resorption side rather than the osteoblast/bone building side. Different 
factors and cytokines have been found to either promote or inhibit bone resorption and therefore 
the activity of osteoblasts and osteoclasts (Huang, et al., 2014) (Shaw, et al., 2016). Cytokines that 
inhibit bone resorption and aid the osteoblasts include IL-4, IL-10, IFN-g and IL-12/18, whereas 
those that promote bone resorption and aid osteoclasts include IL-1b, TNF-a, IL-6 and IL-17 (Wan, 
et al., 2016). Other influencers to bone builders are growth factors such as TGF-b and BMP 2-4, 
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and hormones, such as calcitonin and estrogens (Wan, et al., 2016). However, lipid mediators such 
as PGE2 have been found to assist in bone breakdown. Vitamin D is a unique factor in that con-
tradictory studies have found it to either assist or hinder bone formation according to the matura-
tion stage in which it was studied as well as the skeletal origin of the osteoblasts (Wan, et al., 
2016). A possible link was also identified by Wu et al. between vitamin D binding protein and 
generalized aggressive periodontitis (Wu, et al., 2009).  
Vitamin D is a fat-soluble molecule that has been shown by many studies to have an effect 
on mineral ion homeostasis (Kawakami, et al., 2004). Vitamin D is also essential for the differen-
tiation and maturation of osteoblasts (Anderson, 2017) (Tsuprykova, et al., 2017). Pre-vitamin D 
is obtained either from the skin by sun exposure or ingested from the diet. Fatty fish contain the 
D3 compound of the vitamin whereas fortified foods have the D2 form (van den Ouweland, et al., 
2013) (Tsuprykova, et al., 2017).  In order for the actions of vitamin D to occur it must be converted 
into the active form 1,25 OH2D by processes in the liver and kidneys (van der Meijen, et al., 2014). 
The active form of vitamin D works on vitamin D receptors in the osteoblasts and other cells to 
perform its functions (Bikle, 2014). This may be another factor into play with the osteoblast activ-
ity in that studies have shown that 25OHD may assist in bone building by osteoblasts whereas 
1,25OHD stimulates bone resorption (Anderson, 2017) (Yang, et al., 2016) (Turner, et al., 2014). 
Studies done on hemodialysis patients have found that 25OHD suppress osteoclast action in cases 
of inflammation by increasing expression of RANKL and inducing the production of OPG 
(Eleftheriadis, et al., 2012).  
Vitamin D has also been shown to be a potent differentiator of osteoblast-like MC3T3-E1 
cells into osteoblasts. Kim et al. showed that 1,25OHD increase cell proliferation and ALP activity. 
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Gene expressions of ALP, Col-I, OCN and VDR were also increased in osteoblasts with 1,25OHD 
induction (Kim, et al., 2018).  However, Vit D receptors for 1,25OHD have been observed to have 
different effects depending on the age of the osteoblasts. In early stages, it seems to inhibit the 
differentiation into osteoblasts. However, in later stages, it seems to increase osteoblastic activity  
(St- Arnaud, 2008). Van Driel et al found that 1,25OHD decreases osteoblasts proliferation but 
increases differentiation by increasing collagen type I synthesis, osteocalcin and osteopontin (van 
Driel, et al., 2004). 2 
5OHD was thought to only have effects on osteoblasts after conversion to 1,25OHD, be-
cause osteoblasts are capable of synthesizing 1,25OHD from 25OHD by expressing 1a-hydrox-
ylase. While studying the effects of 25OHD on osteoblasts, they found that it increases the ALP 
activity and osteocalcin expression (van der Meijen, et al., 2014) (van Driel, et al., 2004). It is 
currently unknown if these effects occur only after conversion or if 25OHD has a cellular effect of 
its own, but silencing CYP27B1 human osteoblasts cell studies have shown that 25OHD decreases 
osteonectin and CYP24 mRNA expression compared to controls (van der Meijen, et al., 2014).  
Alkaline phosphatase (ALP) is a glycoprotein produced by fibroblasts, osteoblasts and os-
teoclasts. It plays a role in mineral formation of hard tissue structures like bone and cementum as 
first studied by Robinson in 1923 (Robison, et al., 1924) (Farahani, et al., 2015). It is known to be 
a biological marker of osteoblastic activity during bone deposition (Farahani, et al., 2015) (Rodan, 
1992). 
The MAPK (mitogen-activated protein kinase) pathway is one of the major pathways in-
volved in bone remodeling and has also been shown to be activated during orthodontic tooth move-
34 
 
ment (Jiang, et al., 2018). It is composed of a multiple Ser/Thr kinases including ERK (extracel-
lular signal-regulated kinase) 1/2, p38 and JNK (c-Jun-N-terminal kinase) (Jiang, et al., 2018). 
These signals are closely associated with bone formation of osteoblasts and bone resorption of 
osteoclasts mainly in the areas of proliferation, apoptosis and differentiation (Jiang, et al., 2018). 
There is a contradictory evidence of the full mechanism of ERK1/2 and p38 pathways in osteo-
genic differentiation (Li, et al., 2012) (Xiao, et al., 2002) (Jiang, et al., 2018). Li et al showed an 
increase in osteogenic differentiation when ERK 1/2 and p38 signaling pathways we inhibited in 
dental follicle cells (Li, et al., 2012). However, Xiao et al reported restrained osteoblastic activity 
and bone formation due to inhibition of the ERK1/2 pathway (Xiao, et al., 2002).  
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Hypothesis 
Null Hypothesis: (H0): There is no correlation between different concentrations of 1,25OHD and 
25OHD with osteoblast functions. 
Hypothesis: (H1): Different concentrations of 1,25OHD and 25OHD will impact osteoblast func-
tions 
 
Aims 
Overall aim 
The aim of this study was to determine the impact of different concentrations of 1,25OH Vitamin 
D and 25OH Vitamin D on osteoblast function and signaling pathway 
Specific aims 
1) To determine the impact of vitamin D’s effect on OPG, RANKL and ALP production by 
the osteoblasts 
2) To identify the signaling pathways that 1,25OHD and 25OHD stimulate in osteoblasts 
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Materials and Methods 
Cell Culture 
Osteoblasts were collected from the calvaria of 3-5 day old healthy FVB wild-type mice 
purchased from Jackson Laboratories (Bar Harbor, ME) in conformity with the standards of the 
Public Health Service Policy on Human Care and the Use of Laboratory Animals and were ap-
proved by the Institution of Animal Care and Use Committee of the Forsyth Institute. 
 The frontal and parietal bones were aseptically isolated by dissection of the scalp skin, 
periosteum and loosely adherent tissues. They were immediately rinsed with ethanol and phos-
phate-buffered saline (PBS) + antibiotics (penicillin/streptavidin) to remove all extraneous tissue. 
The calvaria were then washed with a solution of 137 mM NaCl, 2.7 mM KCl and 3 mM NaH2PO4 
x H2O and incubated for 10 minutes on a shaker at 37°C in 4 mM After that, a Na2-EDTA solution, 
three times to demineralize the extracellular matrix discarding the supernatants. They were then, 
incubated a total of 7 times at 37°C in a freshly prepared collagenase type 2 solution (Worthington) 
in 137 mM NaCl, 2.7 mM KCl, 3mM NaH2PO4 x H2O on a shaker to separate the cells from the 
extracellular matrix. The first 2 supernatants were discarded, and the supernatants from the fol-
lowing five incubations were collected, pooled, centrifuged, and re-suspended in α-MEM media 
supplemented with 10% FBS, 10,000 IU penicillin (1%), and 10,000 μg/ml streptomycin (1%). 
Cells were cultured in 75 ml flasks with MEM Alpha (1X) media with L-Glutamine, Ribonucleo-
tides and Deoxy-ribonucleotides from Gibco™ including 10% FBS (fetal bovine serum) and 1% 
penicillin and streptomycin until they reached 90% confluency. Once the cells had grown enough, 
they were seeded depending on the experiment and treated with 25OHD3 (10-8 M) and 1a25OHD3 
(10-8 M) in varying dosages, 25OHD (0, 100, 200 or 400 nmol/L) and 1a25OHD (0, 1, 10 or 100 
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nmol/L). The media was changed every 3 days. All experiments were repeated 3-5 times and av-
erages used for statistical calculations. 
Measurement of Alkaline Phosphatase (ALP) in Osteoblast Culture Supernatants 
 Osteoblasts were seeded in 24-well plates at 2x104 cells/well in triplicate with MEM Alpha 
(1X) from Gibco™ including 10% FBS and 1% penicillin/ streptomycin with the appropriate con-
centrations of 1,25OHD (1, 10,100nmol) and 25OHD (100, 200, 400 nmol) as well as control 
sample. Supernatant of cells was collected at days 3, 7, and 10 with each media change. Then the 
collected samples were measured using Abcam Alkaline Phosphatase Assay kit (Colorimetric) 
(ab83369) according to manufacturer’s instructions. Optical density (OD) of the products at 405 
nm was measured by spectrophotometry. Enzyme activity was calculated as the OD of the reaction 
product multiplied by the reaction volume and normalized to the reaction time and to the total 
protein.  
Measurement of Osteoprotegerin (OPG) and RANKL in Osteoblast Culture Supernatants 
Osteoblasts were obtained as explained above and seeded in 24-well plates at 1x104 
cells/well in triplicate with MEM Alpha (1X) from Gibco™ including 10% FBS and 1% penicillin/ 
streptomycin with the appropriate concentrations of 1,25OHD (1, 10,100nmol) and 25OHD (100, 
200, 400 nmol) as well as a control sample. Supernatant of cells was collected at days 3, 7, and 10 
with each media change. OPG and RANKL levels were measured using the Quantikine DuoSet 
ELISA (enzyme-linked immunosorbent assay) kit by R&D systems according to manufacturer’s 
instructions. ELISA plates were coated with the OPG, RANKL (R&D Systems) capture antibodies 
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overnight, then washed with 0.05% Tween® 20 in PBS, blocked using 1% BSA in PBS, and incu-
bated with standards and samples. The detection antibody diluted in 1% BSA in PBS was applied 
to the plates, followed by Avidin-HRP in 1% BSA in PBS. The colorimetric signal developed after 
incubation with 1:1 mixture of H2O2 and Tetramethylbenzidine, and the reaction was stopped using 
2N H2SO4. Absorbance was read at 450 nm (Spectramax 340PC 384 with a SoftMax Pro software 
4.3LS, Molecular Devices), and the background absorbance values were subtracted. Sample con-
centration was calculated based on a standard curve. 
Measurement of Osteoprotegerin (OPG) and RANKL Expression in Osteoblasts 
 Osteoblasts were seeded into 6-well plates at 1x105 cells/well with MEM Alpha (1X) from 
Gibco™ including 10% FBS and 1% penicillin/ streptomycin with the appropriate concentrations 
of 1,25OHD (1, 10,100nmol) and 25OHD (100, 200, 400 nmol) as well as a control sample. Cells 
were lysed at 3, 7, and 10 days using the RNeasy Plus kit from Qiagen. Media was removed from 
each well and the appropriate amount of lysate was added to disrupt and homogenize the cells. An 
equal amount of ethanol was then added to each condition to promote selective binding of RNA 
to RNeasy membrane. Then the mixture was transferred to a RNeasy spin column and centrifuged 
at > 8000 x g for 15 sec. The process was repeated with the appropriate buffers (RW1 once and 
RPE twice). The spin column was then placed in a new 2ml collection tube and centrifuged at full 
speed for 1 min to eliminate any residual buffers. 40 μg of RNase free water to elute the RNA. 
Purity of RNA was confirmed by a 260/280 optical density value of 1.8-2.0 by Nanodrop.  
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 cDNA was generated using reverse transcription using Invitrogen SuperScript IV VILO 
kit per manufacturer’s protocol for qRTPCR (protocol in appendix below). Reverse transcription 
reaction was performed using 1 pg RNA using random hexamers, dNTP, buffer, nuclease-free 
water, ribonuclease (RNase) inhibitor and reverse transcriptase (High-Capacity cDNA Reverse 
Transcription Kit, ABI). The samples were incubated in the GeneAmp PCR 9700 system (ABI): 
25°C for 10 min, 37°C for 2 h, 85°C for 5 min with a total of 20 μl reaction volume. The cDNA 
products were stored at -20°C and diluted before the real-time reaction. 
The expression of the OPG and RANKL genes in osteoblasts was measured with quantita-
tive real-time PCR and analyzed using the ΔCT and ΔΔCT method. The expression of each target 
gene was calculated relative to GAPDH endogenous control, relative to the 3 day controls. The 
following equations were used to calculate the ∆CT and ∆∆CT for OPG and RANKL results nor-
malized to GADPH. 
∆𝐶𝑇 = 𝑥𝐶𝑇	(𝑠𝑎𝑚𝑝𝑙𝑒) − 	𝑥𝐶𝑇	(𝐺𝐴𝐷𝑃𝐻) 
  𝑐 = 𝑥∆𝐶𝑇	(𝑠𝑎𝑚𝑝𝑙𝑒) − 𝑥∆𝐶𝑇	(3𝑑𝑎𝑦	𝑐𝑜𝑛𝑡𝑟𝑜𝑙) 
Measurement of total protein concentration 
Protein concentration was measured using the BCA (Bicinchoninic acid assay) kit by Ther-
moFisher Scientific. A standard curve was prepared using serial dilutions of bovine serum albumin 
(BSA) at 0, 5, 25, 50, 125, and 250 μg/ml. 200 μl BCA reagent (Pierce™ BCA Protein Assay Kit) 
were added to 10 μl sample and standards and assayed in duplicates. Absorbance was measured at 
562 nm (Spectramax 340PC384 with SoftMax 4.3LS, Molecular Devices). Background absorb-
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ance of de-ionized water was subtracted from all measurements. Sample concentrations were ex-
trapolated from the standard curve. Western Blot was then performed according to the methodol-
ogy below. 
Measurement of ERK1/2, p38 and NLK in Osteoblasts 
 Osteoblasts were seeded into 6-well plates at 1x105 cells/well with MEM Alpha (1X) from 
Gibco™ including 10% FBS and 1% penicillin/ streptomycin with the appropriate concentrations 
of 1,25OHD (1, 10,100nmol) and 25OHD (100, 200, 400 nmol) as well as a control sample. Cells 
were lysed and scraped at 1-hour and 24-hours using the appropriate amount of Cell Lysate pro-
vided by ThermoFisher Scientific supplemented with protease and phosphatase inhibitors. Anti-
bodies chosen according to the MAPK pathway as ERK1/2 (p44/42 MAPK), Total ERK 1/2, p-
p38, Total p-38 and NLK using B-actin as a control. Antibodies were purchased from Cell Signal-
ing Technology. 
5ug of lysate of each sample was calculated according to the BCA assay and mixed with 
4x sample loading buffer with 2.5% volume β-ME then denatured by heating to 100°C for 8 min. 
Electrophoresis was done to the lysate samples in 12% polyacrylamide gels in running buffer (25 
mM Trizma base, 192 mM glycine, 0.1% sodium dodecyl sulfate (SDS)) at 100 V for 1.5-2 hrs. 
Molecular weight standard (ladder) was added in a separate well in the gel. A polyvinylidene flu-
oride (PVDF) membrane was prepared by 1 min incubation in methanol followed by 10 min incu-
bation in blotting buffer (25 mM Trizma base, 192 mM glycine, 20% 79 methanol). Transfer of 
the proteins to the PVDF membrane was performed at 4°C overnight at 66 mA. The next morning, 
the membrane was incubated in blocking solution (5% (w/v) BSA in 20 mM Tris-HCI, 150 mM 
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NaCl, 0.1% Tween-20 + 5% BSA (TBS-T)) for 1 hour and then incubated with the targeted pri-
mary antibodies overnight at 4°C in 5% BSA in TBS-T on a shaker. The next day, the membrane 
was washed 3 times with TBS-T for 10 min and incubated with goat anti-rabbit IgG-horseradish 
peroxidase (HRP) secondary antibody in blocking solution (5% (w/v) milk in 20 mM Tris-HCI, 
150 mM NaCl, 0.1% Tween-20 + 5% milk (TBS-T)) for 1 hr. at room temperature. The membrane 
was then washed 3 times for 10 min in TBS-T, and the HRP conjugate was detected using a chem-
iluminescence reaction. An X-ray film was exposed to the membrane and protein bands were vis-
ualized. Results were normalized to the expression of (β-actin). To assay for additional targets, the 
membrane was incubated for 20 min in a stripping buffer and washed 3 times in TBS-T before 
incubation with the next primary antibody. 
Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism 8 Software 2019 (San Diego, 
California) for regression, one way ANOVA, and Tukey Post-hoc analysis as needed. The level of 
significance was noted at p<0.05 for all analyzed data. All tests were performed 3-5 times in du-
plicate and the means entered for statistical analysis. 
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Results 
Measurement of Alkaline Phosphatase Concentration and Activity in Osteoblast Supernatant 
 ALP concentration and activity were measured using the Abcam Alkaline Phosphatase As-
say kit (Colorimetric) kit (ab83369) explained above. Supernatants were collected at 3, 7, and 10 
days in triplicate of 20,000 cells/well. Results were measured using a statistical analysis system 
STATA and Graphpad Prism 8. No significant differences were noted between groups or between 
different time-points of the same group.  
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 ALP concentration stdev ALP Activity stdev 
3 days     
      Control 8.572 2.169 1.818 0.515 
      1,25OHD 1nmol 8.438 1.390 1.805 0.311 
      1,25OHD 10nmol 8.613 1.580 1.833 0.367 
      1,25OHD 100nmol 8.777 2.154 1.888 0.495 
      25OHD 100nmol 8.704 1.828 1.868 0.417 
      25OHD 200nmol 9.621 3.489 2.101 0.801 
      25OHD 400nmol 8.748 2.179 1.905 0.480 
7 days     
      Control 9.230 2.047 1.975 0.474 
      1,25OHD 1nmol 8.888 2.283 1.909 0.529 
      1,25OHD 10nmol 9.058 1.730 1.944 0.389 
      1,25OHD 100nmol 9.687 2.999 2.081 0.703 
      25OHD 100nmol 8.898 1.977 1.926 0.438 
      25OHD 200nmol 8.766 2.020 1.864 0.476 
      25OHD 400nmol 8.824 1.984 1.892 0.457 
10 days     
      Control 9.242 2.381 1.950 0.569 
      1,25OHD 1nmol 8/644 2.036 1.812 0.489 
      1,25OHD 10nmol 9.261 2.192 1.970 0.517 
      1,25OHD 100nmol 9.503 2.585 1.995 0.621 
      25OHD 100nmol 8.721 2.270 1.828 0.545 
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      25OHD 200nmol 8.592 2.239 1.812 0.535 
      25OHD 400nmol 9.421 1.978 1.975 0.475 
Table 5: ALP concentration and activity means and standard deviations 
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Figure 1: ALP Concentration in pg/ml between groups over time. No statistical significance (at 
p<0.05) between groups over time.  
A. at 3 days.  
B. at 7 days.  
C. at 10 days. 
Conditions: control, 1,25OHD 1nmol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 
25OHD 200nmol, 25OHD 400nmol. 
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Figure 2: ALP Concentration in pg/ml between time points within groups. No statistical signifi-
cance (at p<0.05) between time points within groups.  
A. Control condition with days 3, 7, and 10 
B. 1,25OHD 1nmol condition with days 3, 7, 10 
C. 1,25OHD 10nmol condition with days 3, 7, 10 
D. 1,25OHD 100nmol condition with days 3, 7, 10 
E. 25OHD 100nmol condition with days 3, 7, 10 
F. 25OHD 200nmol condition with days 3, 7, 10 
G. 25OHD 400nmol condition with days 3, 7, 10 
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Figure 3: ALP Activity (µM/min/mg protein) between groups over time. No statistical significance 
(at p<0.05) between groups over time. 
A. at 3 days. 
B. at 7 days.  
C. at 10 days. 
Conditions: control, 1,25OHD 1nmol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 
25OHD 200nmol, 25OHD 400nmol. 
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Figure 4: ALP Activity (µM/min/mg protein) between time points within groups. No statistical 
significance (at p<0.05) between time points within groups. 
A. Control condition with days 3, 7, and 10 
B. 1,25OHD 1nmol condition with days 3, 7, 10 
C. 1,25OHD 10nmol condition with days 3, 7, 10 
D. 1,25OHD 100nmol condition with days 3, 7, 10 
E. 25OHD 100nmol condition with days 3, 7, 10 
F. 25OHD 200nmol condition with days 3, 7, 10 
G. 25OHD 400nmol condition with days 3, 7, 10 
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Measurement of OPG and RANKL Levels in Osteoblasts Supernatant 
OPG and RANKL concentration were measured using the Quantikine DuoSet kit by R&D 
systems according to manufacturer’s instructions explained above. Supernatant was collected at 3, 
7, and 10 days in triplicate of 10,000 cells/well. Results were measured using statistical analysis 
system STATA. Using one-way ANOVA and Tukey Post-hoc, the following statistically signifi-
cant results were observed. 
 In regards to OPG levels at 3 days, a significant difference was noted between control and 
25OHD 100nmol (0.0171), 1,25OHD 1nmol and the 25OHD 100nmol (p=0.0005), 1,25OHD 
10nmol and 25OHD 100nmol (p=0.0001), 1,25OHD 100nmol and 25OHD 100nmol (p=0.0011) 
and 25OHD 100nmol and 25OHD 400nmol (p=0.0193). At 7 days, the significant differences were 
noted between the control and 25OHD 100nmol (p=0.0043), 1,25OHD 1nmol and 25OHD 
100nmol (p=0.0001) and 25OHD 200nmol (p=0.0224). 1,25OHD 10nmol was noted to be signif-
icantly associated with both 25OHD 100nmol and 200nmol (p=0.000 and 0.0116, respectively). 
However, 1,25OHD at 100nmol was significant with 25OHD 100 nmol and 400nmol (p=0.000 
and 0.0016, respectively). Lastly with 7 days, 400nmol of 25OHD was statistically significant with 
25OHD 100nmol and 200nmol (p=0.000 and 0.0018, respectively). With 10 days, the significant 
differences were noted with control and 25OHD 100nmol (p=0.0175), 25OHD 100nmol with 
1,25OHD 1nmol (p=0.0118), 1,25OHD 10nmol (p=0.0094) and 1,25 100nmol (p=0.0020). Fi-
nally, 10 day 25OHD 100nmol and 25OHD 400nmol (p=0.0018). 
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 When considering OPG levels by group over time points, the only differences were found 
in 25OHD 200nmol and 25OHD 400nmol. For the 200nmol concentration the difference was 
noted between day 7 and day 10 (p=0.0000). For the 400nmol concentration the difference was 
noted between days 3 and 10 (p=0.0377). 
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 OPG stdev RANKL stdev 
3 days     
      Control 20,353.07 25,513.30 19.14 17.62 
      1,25OHD 1nmol 11,316.26 8,562.44 29.77 31.71 
      1,25OHD 10nmol 6,510.57 2,832.54 54.25 32.11 
      1,25OHD 100nmol 3,678.50 1,044.30 97.63 118.04 
      25OHD 100nmol 14,706.47 13,323.73 26.40 20.44 
      25OHD 200nmol 11,993.36 10,688.58 22.67 19.56 
      25OHD 400nmol 7,799.88 6,645.57 41.22 36.94 
7 days     
      Control 13,495.80 12,363.04 26.96 22.11 
      1,25OHD 1nmol 10,695.70 7,366.23 25.95 18.41 
      1,25OHD 10nmol 5,6775.88 1,228.76 56.01 40.62 
      1,25OHD 100nmol 1,364.49 479.27 44.86 26.66 
      25OHD 100nmol 17,773.36 18,71.96 27.36 20.89 
      25OHD 200nmol 15,627.60 21,733.22 22.67 23.27 
      25OHD 400nmol 4,615.41 5,586.43 64.03 72.28 
10 days     
      Control 6,222.13 930.27 23.94 18.66 
      1,25OHD 1nmol 16,123.50 19,227.94 21.92 12.66 
      1,25OHD 10nmol 9,911.01 14,806.31 34.04 19.62 
      1,25OHD 100nmol 2,358.66 3,173.24 130.76 187.96 
      25OHD 100nmol 20,514.57 24,658.17 21.22 17.16 
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      25OHD 200nmol 17,909.90 25,030.23 16.16 11.03 
      25OHD 400nmol 3,497.77 4,696.84 59.40 74.97 
Table 6: OPG and RANKL concentrations and standard deviations 
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Figure 5: OPG concentration in pg/ml by time points over groups. 
A. at 3 days.  
B. at 7 days.  
C. at 10 days. 
Conditions: control, 1,25OHD 1nmol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 
25OHD 200nmol, 25OHD 400nmol. 
* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001  
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3 day Con-
trol 
1,25OHD 
1nmol 
1,25OHD 
10nmol 
1,25OHD 
100nmol 
25OHD 
100nmol 
25OHD 
200nmol 
25OHD 
400nmol 
Control - 0.6289 0.2140 0.1457 0.0171 0.8262 0.1212 
1,25OHD 1nmol 0.6289 - 0.9821 0.9427 0.0005 0.9998 0.9137 
1,25OHD 10nmol 0.2140 0.9821 - >0.9999 0.0001 0.9029 0.9999 
1,25OHD 100nmol 0.1457 0.9427 >0.9999 - <0.0001 0.8081 >0.9999 
25OHD 100nmol 0.0171 0.0005 0.0001 <0.0001 - 0.0011 <0.0001 
25OHD 200nmol 0.8262 0.9998 0.9029 0.8081 0.0011 - 0.7552 
25OHD 400nmol 0.1212 0.9137 0.9999 >0.9999 <0.0001 0.7552 - 
 
7 day Con-
trol 
1,25OHD 
1nmol 
1,25OHD 
10nmol 
1,25OHD 
100nmol 
25OHD 
100nmol 
25OHD 
200nmol 
25OHD 
400nmol 
Control - 0.4099 0.2645 0.0517 0.0043 0.7024 0.0579 
1,25OHD 1nmol 0.4099 - 0.9999 0.8958 0.0001 0.0224 0.9148 
1,25OHD 10nmol 0.2645 0.9999 - 0.9722 0.0000 0.0116 0.9798 
1,25OHD 100nmol 0.0517 0.8958 0.9722 - 0.0000 0.0016 1.0000 
25OHD 100nmol 0.0043 0.0001 0.0000 0.0000 - 0.1222 0.0000 
25OHD 200nmol 0.7024 0.0224 0.0116 0.0016 0.1222 - 0.0018 
25OHD 400nmol 0.0579 0.9148 0.9798 1.000 0.0000 0.0018 - 
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10 day Con-
trol 
1,25OHD 
1nmol 
1,25OHD 
10nmol 
1,25OHD 
100nmol 
25OHD 
100nmol 
25OHD 
200nmol 
25OHD 
400nmol 
Control - 1.0000 0.9999 0.9559 0.0175 0.9520 0.9455 
1,25OHD 1nmol 1.0000 - 1.0000 0.9836 0.0118 0.9005 0.9783 
1,25OHD 10nmol 0.9999 1.0000 - 0.9922 0.0094 0.8589 0.9890 
1,25OHD 100nmol 0.9559 0.9836 0.9922 - 0.0020 0.4716 1.0000 
25OHD 100nmol 0.0175 0.0118 0.0094 0.0020 - 0.1329 0.0018 
25OHD 200nmol 0.9520 0.9005 0.8589 0.4716 0.1329 - 0.4454 
25OHD 400nmol 0.9455 0.9783 0.9890 1.0000 0.0018 0.4454 - 
Table 7: OPG statistical significance by one way ANOVA over time points 
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Figure 6: OPG concentration in pg/ml by groups over time points 
A. Control condition with days 3, 7, and 10 
B. 1,25OHD 1nmol condition with days 3, 7, 10 
C. 1,25OHD 10nmol condition with days 3, 7, 10 
D. 1,25OHD 100nmol condition with days 3, 7, 10 
E. 25OHD 100nmol condition with days 3, 7, 10 
F. 25OHD 200nmol condition with days 3, 7, 10 
G. 25OHD 400nmol condition with days 3, 7, 10 
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 3-7 day 3-10 day 7-10 day 
Control 0.9966 0.7539 0.7972 
1,25OHD 1nmol 0.9573 0.8712 0.7204 
1,25OHD 10nmol 0.9736 0.6625 0.7890 
1,25OHD 100nmol 0.2563 0.4631 0.8884 
25OHD 100nmol 0.9985 0.6666 0.5929 
25OHD 200nmol 0.0625 0.0623 >0.9999 
25OHD 400nmol 0.1346 0.0377 0.6981 
Table 8: OPG statistical significance over groups by time points 
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 When looking into RANKL levels over time, the following combinations were considered 
statistically significant. At 3 days, control with 25OHD 400nmol at p=0.0125 and 25OHD between 
the 100 and 400nmol concentrations (p=0.0128). In the 7-day time-point, the 25OHD 400nmol 
was statistically significant with all of the following, control (p=0.0010), 1,25OHD 1nmol 
(p=0.0054), 1,25OHD 10nmol (p=0.0040), 1,25OHD 100nmol (p=0.0309), 25OHD 100nmol 
(p=0.0008) and 25OHD 200nmol (p=0.0008). However, the 10-day time point showed no statisti-
cally significant difference between any combinations. When considering by group, the only sig-
nificance was in the 1,25OHD 10nmol group between days 3 and 7 (p=0.0009) and days 3-10 
(p=0.0001). 
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Figure 7: RANKL concentration in pg/ml by time points over groups  
A. at 3 days. 
B. at 7 days. 
C. at 10 days. 
Conditions: control, 1,25OHD 1nmol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 
25OHD 200nmol, 25OHD 400nmol. 
* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001  
 
 
 
 
 
60 
 
3 day Con-
trol 
1,25OHD 
1nmol 
1,25OHD 
10nmol 
1,25OHD 
100nmol 
25OHD 
100nm
ol 
25OHD 
200nmol 
25OHD 
400nmol 
Control - 0.9789 0.4593 0.1160 0.8031 0.9494 0.0125 
1,25OHD 1nmol 0.9789 - 0.9073 0.4443 0.9799 >0.9999 0.0735 
1,25OHD 10nmol 0.4593 0.9073 - 0.9754 0.4639 0.9538 0.4901 
1,25OHD 100nmol 0.1160 0.4443 0.9754 - 0.1177 0.5428 0.9328 
25OHD 100nmol 0.8031 0.9799 0.4639 0.1177 - 0.9512 0.0128 
25OHD 200nmol 0.9494 1.0000 0.9538 0.5428 0.9512 - 0.1019 
25OHD 400nmol 0.0125 0.0735 0.4901 0.9328 0.0128 0.1019 - 
 
7 day Con-
trol 
1,25OHD 
1nmol 
1,25OHD 
10nmol 
1,25OHD 
100nmol 
25OHD 
100nmol 
25OHD 
200nmol 
25OHD 
400nmol 
Control - 0.9888 0.9962 0.7307 1.0000 1.0000 0.0010 
1,25OHD 1nmol 0.9888 - 1.0000 0.9837 0.9787 0.9783 0.0054 
1,25OHD 10nmol 0.9962 1.0000 - 0.9647 0.9913 0.9912 0.0040 
1,25OHD 100nmol 0.7307 0.9837 0.9647 - 0.6726 0.6709 0.0309 
25OHD 100nmol 1.0000 0.9787 0.9913 0.6726 - >0.9999 0.0008 
25OHD 200nmol 1.0000 0.9783 0.9912 0.6709 >0.9999 - 0.0008 
25OHD 400nmol 0.0010 0.0054 0.0040 0.0309 0.0008 0.0008 - 
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10 day Control 1,25OH
D 
1nmol 
1,25OHD 
10nmol 
1,25OH
D 
100nmol 
25OHD 
100nmol 
25OHD 
200nmo
l 
25OHD 
400nmo
l 
Control - 1.0000 0.9997 0.8544 >0.9999 >0.9999 0.0617 
1,25OHD 1nmol 1.0000 - 0.9999 0.8732 >0.9999 >0.9999 0.0675 
1,25OHD 10nmol 0.9997 0.9999 - 0.9671 0.9997 0.9998 0.1270 
1,25OHD 
100nmol 
0.8544 0.8732 0.9671 - 0.8487 0.8603 0.5193 
25OHD 100nmol >0.999
9 
>0.9999 0.9997 0.8487 - 0.9942 0.0601 
25OHD 200nmol >0.999
9 
>0.9999 0.9998 0.8603 0.9942 - 0.0634 
25OHD 400nmol 0.0617 0.0675 0.1270 0.5193 0.0601 0.0634 - 
Table 9: RANKL statistical significance by one way ANOVA over time points 
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Figure 8: RANKL concentration in pg/ml by groups over time points 
A. Control condition with days 3, 7, and 10 
B. 1,25OHD 1nmol condition with days 3, 7, 10 
C. 1,25OHD 10nmol condition with days 3, 7, 10 
D. 1,25OHD 100nmol condition with days 3, 7, 10 
E. 25OHD 100nmol condition with days 3, 7, 10 
F. 25OHD 200nmol condition with days 3, 7, 10 
G. 25OHD 400nmol condition with days 3, 7, 10 
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 3-7 day 3-10 day 7-10 day 
Control 0.2336 0.9987 0.2500 
1,25OHD 1nmol >0.9999 0.3434 0.3409 
1,25OHD 10nmol 0.0009 0.0001 0.2931 
1,25OHD 100nmol 0.5133 0.2931 0.8912 
25OHD 100nmol 0.6336 0.4843 0.9630 
25OHD 200nmol 0.0665 0.0730 0.9980 
25OHD 400nmol 0.8458 0.8806 0.5717 
Table 10: RANKL statistical significance over groups by time points 
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Figure 9: RANKL/OPG by time points showing each condition (control, 1,25OHD 1nmol,  
1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 200nmol, 25OHD 400nmol) 
over days 3, 7, and 10. 
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Figure 10: RANKL/OPG by groups showing days 3, 7, and 10 for each condition; control, 
1,25OHD 1mol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 200nmol, 
25OHD 400nmol. 
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Measurement of OPG and RANKL levels from cDNA by qrtPCR 
qRTPCR results for OPG and RANKL from the cDNA were measured at 3, 7, and 10 days 
using GADPH as the endogenous control as explained above. Results were measured using statis-
tical analysis system STATA.  
With regression analyses, a significant difference (p=0.007) was noted between the 3-day 
control and the 10-day 25OHD at 400nmol concentration for OPG. The ∆∆CT was measured to 
the 3-day control for both OPG and RANKL. Significant differences were noted by ANOVA at 
day 10 with 25OHD between the control and the 400nmol concentration (p=0.04) and between the 
200nmol and 400nmol concentrations (p=0.035). For RANKL, the regression analysis to the 3-
day control showed significant differences with 3-day 25OHD 400nmol concentration (p=0.006), 
7-day 1,25OHD 100nmol (p=0.026) and 10-day 25OHD 400nmol (p=0.031). Using ANOVA, we 
noticed significant differences in 3-day 25OHD 400nmol with control (p=0.037) and 25OHD 
100nmol (p=0.019). Another significant difference was noted in the 7-day data between the 
1,25OHD 1nmol and 1,25OHD 100nmol (p=0.025). 
Paired T-tests were performed between the same groups over different days for both OPG 
and RANKL. With OPG, statistically significant differences were found in the control groups be-
tween days 3 and 7 (p=0.019) and days 7-10 (p=0.0009). In the 1,25OHD 1nmol group, significant 
differences were found between all combinations of days; 3-7 (p=0.0036), 7-10 (p=0.0152) and 3-
10 (0.0029). A p value of 0.01 was noted between days 3-10 within the 1,25OHD 100nmol and 
the 25OHD 100nmol groups. In the 25OHD 200nmol group, significant differences were found 
between all group combinations; 3-7 days (p=0.04), 7-10 day (p=0.01) and 3-10 days (p=0.042). 
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Regarding RANKL, the significant differences were found in the 1,25OHD 1nmol category be-
tween day 7-10 (p=0.04) and in the 25OHD 400nmol category between day 3-7 (p=0.015) and 
days 7-10 (p=0.011).  
In regards to the ∆∆CT measurements with 3day control as the control, significant differ-
ences in OPG in group 1,25OHD 1nmol between day 3 and 7 (p=0.0071) and between days 3 and 
10 (p=0.0016). With the RANKL ∆∆CT, 1,25OHD 1nmol showed differences in days 3-7 
(p=0.054) and 25OHD 400nmol between days 3-7 (p=0.0063) and days 7-10 (p=0.014).  
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OPG 
 OPG DCT STDev OPG DDCT STDev 
3 days     
      Control 6.218 2.546 0.000 0.000 
      1,25OHD 1nmol 6.327 2.032 0.109 0.812 
      1,25OHD 10nmol 6.210 1.886 -0.008 1.010 
      1,25OHD 100nmol 6.500 1.606 0.282 1.853 
      25OHD 100nmol 5.694 2.240 -0.525 0.419 
      25OHD 200nmol 6.143 1.691 -0.075 1.202 
      25OHD 400nmol 7.102 2.069 0.884 0.643 
7 days     
      Control 5.139 2.087 -1.079 0.464 
      1,25OHD 1nmol 4.999 1.874 -1.219 0.754 
      1,25OHD 10nmol 5.520 1.987 -0.544 0.416 
      1,25OHD 100nmol 5.703 1.887 -0.352 0.844 
      25OHD 100nmol 6.285 1.992 0.067 3.016 
      25OHD 200nmol 5.086 2.054 -1.132 0.599 
      25OHD 400nmol 5.013 1.654 -1.205 2.347 
10 days     
      Control 4.854 2.093 -1.364 0.454 
      1,25OHD 1nmol 4.292 0.689 -0.789 0.713 
      1,25OHD 10nmol 5.285 1.895 -0.933 0.956 
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      1,25OHD 100nmol 5.627 1.752 -0.591 1.560 
      25OHD 100nmol 5.080 2.086 -1.138 0.628 
      25OHD 200nmol 4.815 1.976 -1.403 0.750 
      25OHD 400nmol 6.711 1.825 0.493 1.189 
Table 11: OPG DCT and DDCT values 
  
70 
 
Figure 11: OPG ΔCт by time points over groups using GADPH as control and ΔΔCт by time 
points over groups using 3-day control as control 
A. 3day ΔCт showing sample normalization to GADPH for each of control, 1,25OHD 1mol, 
1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 200nmol, 25OHD 
400nmol 
B. 7day ΔCт showing sample normalization to GADPH for each of control, 1,25OHD 1mol, 
1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 200nmol, 25OHD 
400nmol 
C. 10day ΔCт showing sample normalization to GADPH for each of control, 1,25OHD 1mol, 
1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 200nmol, 25OHD 
400nmol 
D. 3day ΔΔCт showing sample normalization to GADPH and 3day control for each of control, 
1,25OHD 1mol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 
200nmol, 25OHD 400nmol 
E. 7day ΔΔCт showing sample normalization to GADPH and 3day control for each of control, 
1,25OHD 1mol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 
200nmol, 25OHD 400nmol 
F. 10day ΔΔCт showing sample normalization to GADPH and 3day control for each of con-
trol, 1,25OHD 1mol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 
200nmol, 25OHD 400nmol 
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Regression ΔCт ΔΔCт 
 3 days 7 days 10 days 3 days 7 days 10 days 
1,25OHD 1nmol 0.941 0.921 0.684 0.894 0.764 0.480 
1,25OHD 10nmol 0.996 0.788 0.736 0.992 0.265 0.566 
1,25OHD 100nmol 0.849 0.692 0.547 0.731 0.137 0.312 
25OHD 100nmol 0.737 0.423 0.876 0.319 0.422 0.697 
25OHD 200nmol 0.962 0.970 0.978 0.884 0.970 0.947 
25OHD 400nmol 0.573 0.929 0.213 0.105 0.928 0.007 
Table 12: OPG ΔCт and ΔΔCт regression analysis between groups 
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Delta CT OPG    
 3 days 7 days 10 days 
1,25OHD 0.9967 0.9519 0.7771 
25OHD 0.8261 0.7669 0.5074 
 
Delta Delta CT OPG    
 3 days 7 days 10 days 
1,25OHD 0.981 0.228 0.7562 
25OHD 0.090 0.765 0.017 
 Between day 10 and 25OHD 
 Control  25OHD 100nmol 25OHD 200nmol 
25OHD 100nmol 1   
25OHD 200nmol 1 1  
25OHD 400nmol 0.040 0.085 0.035 
Table 13: OPG ΔCт and ΔΔCт ANOVA over time points 
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Figure 12: OPG ΔCт by time points using GADPH as control 
A. Control condition with days 3, 7, and 10 
B. 1,25OHD 1nmol condition with days 3, 7, 10 
C. 1,25OHD 10nmol condition with days 3, 7, 10 
D. 1,25OHD 100nmol condition with days 3, 7, 10 
E. 25OHD 100nmol condition with days 3, 7, 10 
F. 25OHD 200nmol condition with days 3, 7, 10 
G. 25OHD 400nmol condition with days 3, 7, 10 
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 Day 7 - Day 3 Day 10 – Day 3 Day 10 – Day 7 
Control 0.0188 0.0092 0.0009 
1,25OHD 1nmol 0.0026 0.0152 0.0029 
1,25OHD 10nmol 0.0813 0.0564 0.1470 
1,25OHD 100nmol 0.3950 0.0113 0.0501 
25OHD 100nmol 0.6798 0.0100 0.3880 
25OHD 200nmol 0.0399 0.0101 0.0421 
25OHD 400nmol 0.0923 0.2559 0.0610 
Table 14: OPG ΔCт paired T Test between groups 
76 
 
Figure 13: OPG ΔΔCт values to 3 day control by time points 
A. Control condition with days 3, 7, and 10 
B. 1,25OHD 1nmol condition with days 3, 7, 10 
C. 1,25OHD 10nmol condition with days 3, 7, 10 
D. 1,25OHD 100nmol condition with days 3, 7, 10 
E. 25OHD 100nmol condition with days 3, 7, 10 
F. 25OHD 200nmol condition with days 3, 7, 10 
G. 25OHD 400nmol condition with days 3, 7, 10 
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 Day 7 - Day 3 Day 10 – Day 3 Day 10 – Day 7 
Control 0.0071 0.0016 0.5511 
1,25OHD 1nmol 0.0826 0.2683 0.7127 
1,25OHD 10nmol 0.6508 0.3098 0.7932 
1,25OHD 100nmol 0.8211 0.6926 0.9716 
25OHD 100nmol 0.8884 0.8808 0.6245 
25OHD 200nmol 0.2632 0.1415 0.9034 
25OHD 400nmol 0.1969 0.9337 0.3206 
Table 15: OPG ΔΔCт paired T Test between groups   
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RANKL 
 RANKL DCT STDev RANKL DDCT STDev 
3 days     
      Control 5.743 3.533 0.000 0.000 
      1,25OHD 1nmol 4.522 2.810 -1.221 2.035 
      1,25OHD 10nmol 4.710 3.019 -1.023 2.228 
      1,25OHD 100nmol 3.755 2.622 -1.988 1.596 
      25OHD 100nmol 6.130 2.788 0.387 1.080 
      25OHD 200nmol 5.318 2.614 -0.425 2.717 
      25OHD 400nmol 2.224 3.377 -3.520 0.670 
7 days     
      Control 6.087 3.923 0.343 1.112 
      1,25OHD 1nmol 7.150 3.004 1.407 0.537 
      1,25OHD 10nmol 5.354 3.777 -1.327 1.901 
      1,25OHD 100nmol 4.287 3.660 -2.394 2.01 
      25OHD 100nmol 7.207 3.307 1.464 0.559 
      25OHD 200nmol 6.095 3.173 0.352 0.532 
      25OHD 400nmol 5.898 1.985 0.155 1.840 
10 days     
      Control 5.600 2.308 -0.144 1.437 
      1,25OHD 1nmol 5.962 2.579 -0.851 1.052 
      1,25OHD 10nmol 4.637 3.109 -0.050 0.368 
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      1,25OHD 100nmol 4.391 2.397 -1.352 1.892 
      25OHD 100nmol 6.026 2.568 0.283 1.959 
      25OHD 200nmol 5.740 2.254 -0.003 2.121 
      25OHD 400nmol 2.693 3.049 -3.050 0.930 
Table 16: RANKL DCT and DDCT values 
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Figure 14: RANKL ΔCт over time points by groups using GADPH as control and ΔΔCт by time 
points over groups using 3-day control as control 
A. 3day ΔCт showing sample normalization to GADPH for each of control, 1,25OHD 1mol, 
1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 200nmol, 25OHD 
400nmol 
B. 7day ΔCт showing sample normalization to GADPH for each of control, 1,25OHD 1mol, 
1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 200nmol, 25OHD 
400nmol 
C. 10day ΔCт showing sample normalization to GADPH for each of control, 1,25OHD 1mol, 
1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 200nmol, 25OHD 
400nmol 
D. 3day ΔΔCт showing sample normalization to GADPH and 3day control for each of control, 
1,25OHD 1mol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 
200nmol, 25OHD 400nmol 
E. 7day ΔΔCт showing sample normalization to GADPH and 3day control for each of control, 
1,25OHD 1mol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 
200nmol, 25OHD 400nmol 
F. 10day ΔΔCт showing sample normalization to GADPH and 3day control for each of con-
trol, 1,25OHD 1mol, 1,25OHD 10nmol, 1,25OHD 100nmol, 25OHD 100nmol, 25OHD 
200nmol, 25OHD 400nmol 
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Regression ΔCт ΔΔCт 
 3 days 7 days 10 days 3 days 7 days 10 days 
1,25OHD 1nmol 0.577 0.684 0.857 0.332 0.344 0.521 
1,25OHD 10nmol 0.640 0.779 0.634 0.413 0.147 0.932 
1,25OHD 100nmol 0.369 0.494 0.521 0.125 0.026 0.248 
25OHD 100nmol 0.863 0.627 0.818 0.721 0.190 0.726 
25OHD 200nmol 0.850 0.997 0.939 0.696 0.991 0.908 
25OHD 400nmol 0.135 0.934 0.135 0.006 0.819 0.031 
Table 17: RANKL ΔCт and ΔΔCт regression analysis between groups 
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Delta CT RANKL    
 3 days 7 days 10 days 
1,25OHD 0.8282 0.7237 0.8268 
25OHD 0.3123 0.9331 0.2704 
 
Delta Delta CT RANKL    
 3 days 7 days 10 days 
1,25OHD 0.4601 0.0185 0.5635 
25OHD 0.0118 0.3891 0.0517 
 Between day 7 and 1,25OHD 
 Control  1,25OHD 1nmol 1,25OHD 10nmol 
1,25OHD 1nmol 1   
1,25OHD 10nmol 0.885 0.157  
1,25OHD 100nmol 0.156 0.025 1 
 Between day 3 and 25OHD 
 Control  25OHD 100nmol 25OHD 200nmol 
25OHD 100nmol 1   
25OHD 200nmol 1 1  
25OHD 400nmol 0.037 0.019 0.077 
Table 18: RANKL ΔCт and ΔΔCт ANOVA over time points 
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Figure 15: RANKL ΔCт by time points using GADPH as control 
A. Control condition with days 3, 7, and 10 
B. 1,25OHD 1nmol condition with days 3, 7, 10 
C. 1,25OHD 10nmol condition with days 3, 7, 10 
D. 1,25OHD 100nmol condition with days 3, 7, 10 
E. 25OHD 100nmol condition with days 3, 7, 10 
F. 25OHD 200nmol condition with days 3, 7, 10 
G. 25OHD 400nmol condition with days 3, 7, 10 
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 Day 7 - Day 3 Day 10 – Day 3 Day 10 – Day 7 
Control 0.5806 0.8544 0.6971 
1,25OHD 1nmol 0.0647 0.5066 0.3990 
1,25OHD 10nmol 06789 0.7277 0.1129 
1,25OHD 100nmol 0.5899 0.0502 0.9252 
25OHD 100nmol 0.1991 0.8301 0.3600 
25OHD 200nmol 0.6137 0.3289 0.7576 
25OHD 400nmol 0.0155 0.097 0.0107 
Table 19: RANKL ΔCт paired T Test between groups 
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Figure 16: RANKL ΔΔCт values to 3 day control by time points 
A. Control condition with days 3, 7, and 10 
B. 1,25OHD 1nmol condition with days 3, 7, 10 
C. 1,25OHD 10nmol condition with days 3, 7, 10 
D. 1,25OHD 100nmol condition with days 3, 7, 10 
E. 25OHD 100nmol condition with days 3, 7, 10 
F. 25OHD 200nmol condition with days 3, 7, 10 
G. 25OHD 400nmol condition with days 3, 7, 10 
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 Day 7 - Day 3 Day 10 – Day 3 Day 10 – Day 7 
Control 0.8921 0.9806 0.7988 
1,25OHD 1nmol 0.0540 0.9219 0.0981 
1,25OHD 10nmol 0.9643 0.7096 0.5594 
1,25OHD 100nmol 0.9502 0.8784 0.7158 
25OHD 100nmol 0.5174 0.9925 0.4542 
25OHD 200nmol 0.8501 0.9513 0.9674 
25OHD 400nmol 0.0063 0.8583 0.0140 
Table 20: RANKL ΔΔCт paired T Test between groups 
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Figure 17: RANKL/OPG ratio ΔCт by time points over groups 
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Figure 18: RANKL/OPG Ratio ΔΔCт by time points over groups using 3 day control as control 
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Western Blot 
 Western blot was performed using the above-mentioned technique on the cell lysates col-
lected  24hrs treatment with the appropriate concentration of 1,25OHD or 25OHD. The signaling 
pathway was assessed according to phosphospecific antibodies in the MAPK pathway; pERK1/2 
(p44/42 MAPK), ERK 1/2(p44/42 MAPK), p-p38, p-38 and NLK using B-actin as a control. These 
antibodies were chosen according to the MAPK pathway to indicate proliferation, apoptosis and 
differentiation, respectively. Quantification was done using ImageJ software. After quantification, 
percentage change was calculated from the plots shown in figure 20 below by the following for-
mula for each of ERK 1/2 and p38.  
=>?@ABCDEFGHI      and      ==JKABCDEFLMN  
 1,25OHD seems to upregulate all three pathways with varying degrees with increasing 
concentrations. 25OHD seems to have an effect only on the ERK 1/2 portion of the pathway which 
downregulates further with increasing the concentration, as shown in figure 21 below. 
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Figure 19: Western blot showing control, 1,25OHD and 25OHD with all concentrations with phos-
pho- and total ERK 1/2, p38 and NLK with B actin as an endogenous control. 
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Figure 20: Quantification plots for pERK 1/2, ERK 1/2, p-p38, p38, NLK and B actin for control, 
1,25OHD (1nmol, 10nmol and 100nmol), 25OHD (100nmol, 200nmol, 400nmol) 
 
         
 
 
 
 
  
pERK ERK        pp38            p38             NLK        B actin
Control
1,25OHD 1nmol
1,25OHD 10nmol
1,25OHD 100nmol
25OHD 100nmol
25OHD 200nmol
25OHD 400nmol
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 ERK 1/2 p38 NLK 
1,25OHD 1nmol 12.74% 25.54% 11.89% 
1,25OHD 10nmol 22.44% 5.05% 36.81% 
1,25OHD 100nmol 18.68% 2.39% 28.93% 
25OHD 100nmol -20.67% -3.07% 6.85% 
25OHD 200nmol -50.05% -2.28% 6.81% 
25OHD 400nmol -55.39% 2.85% -3.50% 
Table 21: Western blot percentage changes in 1,25OHD and 25OHD to control 
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Figure 21: Percentage change in 1,25OHD and 25OHD with increase in concentration with 
pERK 1/2, p-p38 and NLK calculated as phospho/B actin/total for each. 
A. pERK/B actin/ERK percentage change for 1,25OHD with 1nmol, 10nmol and 100nmol 
B. p-p38/B actin/p38 percentage change for 1,25OHD with 1nmol, 10nmol and 100nmol 
C. NLK/B actin percentage change for 1,25OHD with 1nmol, 10nmol and 100nmol 
D. pERK/B actin/ERK percentage change for 25OHD with 100nmol, 200nmol and 400nmol 
E. p-p38/B actin/p38 percentage change for 25OHD with 100nmol, 200nmol and 400nmol 
F. NLK/B actin percentage change for 25OHD with 100nmol, 200nmol and 400nmol 
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Discussion 
In this study we compared the impact of vitamin D on the activity of murine calvarial 
osteoblasts. We used both the active form (1,25OHD) and the circulating form (25OHD) in varying 
concentration (1,25OHD: 1nmol, 10nmol and 100nmol and 25OHD: 100nmol, 200nmol, 
400nmol) along with a control.  
ALP production and activity were used to measure the osteoblastic bone activity of the 
cells. 1,25OHD and 25OHD have been shown to increase ALP activity (Kim, et al., 2018) (van 
der Meijen, et al., 2014) (van Driel, et al., 2004). However, in our study there were no significant 
differences in ALP concentration or activity with different concentrations of 1,25OHD and 
25OHD over any of the measured time points (3 days, 7 days and 10 days). We also measured 
each condition over the 3 timepoints and also found no significant differences. We conclude that 
at 3, 7 and 10 days, different concentrations of 1,25OHD and 25OHD may not impact osteoblastic 
ALP concentration or activity.  
The OPG/RANKL balance is extremely important in bone metabolism and remodeling. In 
previous studies, 1,25OHD and 25OHD reduced primary human osteoblasts proliferation and in-
creased differentiation (Anderson, et al., 2007) (van der Meijen, et al., 2014). We measured levels 
in supernatant using ELISA and in cDNA using qRT-PCR. There seems to be a trend of decreased 
OPG production with the increase of concentration with both 1,25OHD and 25OHD. 25OHD 
seems to have a greater effect on OPG production than 1,25OHD with most of the statistically 
significant correlations around the 100nmol concentration. Changes also seemed to increase as 
time progressed with higher levels at the 10 day time point than the 3 or 7 day. The 25OHD 
400nmol condition showed the greatest change over time especially between the 3 and 10 day time 
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points.  Saturation of product may also be a factor in play in this dynamic. At the 10 day concen-
tration, the most changes occur with the 100nmol concentration, this may be due to saturation of 
the system which may explain the decrease as the concentration increased. We also seem to see an 
opposing reaction with the RANKL levels, which appear to increase as the concentration increases. 
The most significant correlations here appear at the 7 day time point, specifically around the 
25OHD 400nmol condition. When looking at the conditions by groups over timepoints, the levels 
also seemed to increase with increased concentration. The only statistically significant correlations 
were in the 1,25OHD 10nmol condition, specifically between days 3 and 7 and days 3 and 10. 
When considering the RANKL/OPG ratio, the differences seem more pronounced in the 7 day 
time point than in the 3 and 10 day time points. The trend continues toward the RANKL side as 
the concentration increases for both 1,25OHD and 25OHD. These mentioned results lead to the 
conclusion that 25 OHD may affect OPG levels more that 1,25OHD and the opposite for 1,25OHD 
and RANKL levels. 25OHD may be closer related with the bone building aspect of bone remod-
eling and 1,25OHD with the bone resorptive aspect. These effects seem to increase with both con-
centration and time. 
When looking at the OPG and RANKL expression by PCR, we compared the results both 
to an endogenous control GADPH and to the 3 day control. Although the statistics mostly showed 
p values greater than 0.05, there is a clear trend that correlates with the above mentioned ELISA 
results for both OPG and RANKL. OPG cDNA levels seemed to decrease over time for all the 
conditions studied with the most significant differences between days being at the control, 
1,25OHD 1nmol and 25OHD 200nmol concentrations. With RANKL cDNA levels the signifi-
cance was mainly with the 25OHD 400nmol concentration with a slightly similar trend. The dif-
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ferences in the RANKL/OPG ratio with the endogenous control were inconsistent but when com-
paring to the 3 day control we noticed the greatest changes occurring around 3 days. This is diver-
gent to the results seen with the RANKL/OPG ratio with supernatant levels measured by ELISA, 
which may be due to a difference in what is happening on a genetic level (peak day 3) to a protein 
level (peak day 7). However, both levels seem to plateau off at the 10 day time point. This corrob-
orates with what was seen in previous studies by van der Meijen et al (van der Meijen, et al., 2014).  
The Western blot technique showing the protein concentrations of the measured sample 
lysates was done according to the method mentioned above. Using the MAPK pathway, we chose 
ERK 1/2, p38 and NLK as antibodies to indicate proliferation, apoptosis and differentiation of the 
cascade reaction of the pathway. There is a contradictory evidence of the full mechanism of 
ERK1/2 and p38 pathways in osteogenic differentiation (Li, et al., 2012) (Xiao, et al., 2002) (Jiang, 
et al., 2018). In our study, 1,25OHD shows upregulation of each of ERK 1/2, p38 and NLK, 
whereas 25OHD only downregulates the ERK 1/2 portion of the pathway.  
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Conclusions 
In part I, we show that clinical outcomes of orthodontic treatment are associated with a 
range of optimal Vitamin D binding protein (VitDBP) as detected in saliva. LogVitDBP levels 
between 2.75 and 6.48 ng/ml are associated with higher changes in II than above or below sug-
gesting that too low or too high VitDBP is linked to a disruption in clinical response to orthodontic 
treatment. We also show no significant correlation between ALP levels and absolute changes in II 
but significant correlation with VitDBP levels, suggesting that salivary ALP is not a clinically 
relevant measure of orthodontic treatment outcomes. Furthermore, we note significant seasonal 
variation with higher VitDBP levels measured during winter months.   
In part II, we show a decrease in OPG production with higher concentrations of 1,25OHD 
and 25OHD with a corresponding increase in RANKL levels. ALP levels were not significantly 
affected by increasing concentrations of both 1,25OHD and 25OHD which correlates with the 
clinical findings. The ERK 1/2 shows upregulation with 1,25OHD concentrations but downregu-
lation with 25OHD concentrations. P38 and NLK were mainly affected by 1,25OHD and not by 
25OHD suggesting a differential action between both forms of Vitamin D on osteoblast signaling. 
We conclude that vitamin D and its metabolites have an impact on orthodontic tooth move-
ment and osteoblast cellular functions. 
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Appendix 
 
 
RESEARCH SUBJECT INFORMATION AND CONSENT FORM- ADULT 
 
TITLE: The Effects of Vitamin D on Orthodontic Tooth Movement    
 
INVESTIGATOR: Nada Tashkandi 
 
This consent form may contain words that you do not understand.  Please ask the study doctor or the 
study staff to explain any words or information that you do not clearly understand.  You may take 
home an unsigned copy of this consent form to think about or discuss with family or friends before 
making your decision. 
 
PURPOSE OF THE STUDY: 
The purpose of this research study is to measure the effects of Vitamin D levels on the rate of 
Orthodontic tooth movement. We think that hypothesized levels of vitamin D in your body will be 
correlated with how your teeth move when you have your braces on and that that will affect the 
length of treatment. 
 
DESCRIPTION OF THE STUDY 
You will be one of approximately 128 subjects asked to participate in this study. Participating in 
this study will mean that you will be required to spit into a glass tube for each of your first 6 routine 
adjustment appointments after your braces are on. We will measure the level of vitamin D in your 
saliva to compare with the speed of your orthodontic treatment. You will also have an impression 
of your upper and lower teeth made after 6 months (at the end of the study period). This will be 
done for research purposes only. No other changes will be made from your normal orthodontic 
treatment than if you had not participated in the study.  
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RISKS AND DISCOMFORTS 
The only discomfort will be in collecting the saliva into the tube. You will be given ample time to 
allow the saliva to pool into your mouth and dribble it into the tube. The impressions taken will be 
the same as the ones taken in the initial records appointment. 
 
BENEFITS 
Your participation into this study will not affect your orthodontic treatment in any way (neither 
benefit nor worsen). However, it will help in assessing the effects of vitamin D levels on tooth 
movement which will give us a better understanding into how teeth move. 
 
COSTS 
There are no charges for the study visits and they will be taking up 5-10 minutes of your normal 
orthodontic appointment. You will not be reimbursed for participation in this study. 
 
AUTHORIZATION TO USE AND DISCLOSE INFORMATION FOR RESEARCH PUR-
POSES  
Federal regulations give you certain rights related to your health information.  These include the 
right to know who will be able to get the information and why they may be able to get it.  The 
study doctor must get your authorization (permission) to use or give out any health information 
that might identify you.  
Boston Medical Center wants to use and/or share your health information as part of this research 
study. The law requires Boston Medical Center to get your authorization (permission) to do so.   
Health information that might be used or given out during this research includes: 
• Information from your hospital or office health records at Boston Medical Center or 
elsewhere. This applies to information that is reasonably related to the aims, conduct, 
and oversight of the research study. If health information is needed from your doctors 
or hospitals outside of Boston Medical Center, you will be asked to give permission 
for these records to be sent to the researcher. 
• New health information from tests, procedures, visits, interviews, or forms filled out 
as part of this research study. 
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The reasons that your health information might be used or given out to others are: 
• To do the research described here 
• To make sure we do the research according to certain standards set by ethics, law, and 
quality groups or otherwise as required by law 
The people and groups that may use or give out your health information are: 
• Researchers involved in this research study from Boston Medical Center 
• Researchers from other institutions or organizations that are involved in this research 
study 
Other people at Boston Medical Center who may need to access your health information to do 
their jobs such as for treatment, research administration, payment, billing, or health care opera-
tions 
• People or groups that the researchers use to help conduct the study or to provide over-
sight for the study 
• The Institutional Review Board that oversees the research and other people or groups 
that are part of the Human Research Protection Program that oversees the research 
• Research monitors, reviewers, or accreditation agencies and other people or groups that 
oversee research information and the safety of the study 
Some people or groups who get your health information might not be obligated to follow the 
same privacy laws that we follow. We ask anyone who gets your health information from us to 
protect the privacy of your information. However, after your information has been shared with 
others, we cannot promise that it will be kept private. 
  
The time period for using or giving out your health information: 
• Because research is an ongoing process, we cannot give you an exact date when we 
will either destroy or stop using or sharing your health information. 
Your privacy rights are: 
• You have the right not to sign this form that allows us to use and give out your health 
information for research. If you do not sign this form, you cannot be in the research. 
This is because we need to use the health information to do the research. Your deci-
sion not to sign the form will not affect any treatment, health care, enrollment in 
health plans, or eligibility for benefits. 
• You have the right to withdraw your permission to use or share your health infor-
mation in this research study. If you want to withdraw your permission, you must 
write a letter to the Principal Investigator at the address listed on the first page of this 
form. If you withdraw your permission, you will not be able to take back information 
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that has already been used or shared with others. This includes information used or 
shared to do the research study or to be sure the research is safe and of high quality. If 
you withdraw your permission, you cannot continue to be in the study. 
• You have the right to see and get a copy of your health information from the Principal 
Investigator that is used or shared for research.  
The results of this research study may be published in a medical book or journal, or used to teach 
others. However, your name or other identifying information will not be used for these purposes 
without your specific permission.  
 
CONFIDENTIALITY  
Each participant will be given a code and all samples and data will be labeled with this code. Nobody 
other than the PI will be able to identify you with this code. Only the PI will have the master code and 
will keep it in a locked cabinet. Absolute confidentiality cannot be guaranteed because of the need to 
give information to other parties.  The results of this research study may be presented at meetings or 
in publications.  Your identity will not be disclosed in those presentations. 
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
Taking part in this study is voluntary. You have the right to refuse to take part in this study. If you 
decide to be in the study and then change your mind, you can withdraw from the research. Your 
participation is completely up to you. Your decision will not affect your being able to get health care 
at this institution or payment for your health care. It will not affect your enrollment in any health plan 
or benefits you can get.  
If you choose to take part, you have the right to stop at any time. If there are any new findings during 
the study that may affect whether you want to continue to take part, you will be told about them as 
soon as possible. 
The investigator may decide to discontinue your participation without your permission because he/she 
may decide that staying in the study will be bad for you, or the sponsor may stop the study. 
Do not sign this consent form unless you have had a chance to ask questions and have received 
satisfactory answers to all of your questions. You will be given a copy of this form to keep. 
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CONSENT 
I have read the information in this consent form (or it has been read to me).  All my questions about 
the study and my participation in it have been answered.  I freely consent to participate in this research 
study. 
 
By signing this consent form I have not waived any of the legal rights which I otherwise would have 
as a subject in a research study. 
 
You may contact the PI with any questions or concerns at nadatash@bu.edu 
 
CONSENT SIGNATURE: 
 
________________________________________ __________________ 
Signature of Subject Date 
 
________________________________________ 
Printed Name of Subject 
 
________________________________________ 
Signature of PI 
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RESEARCH SUBJECT INFORMATION AND CONSENT FORM-CHILD 
 
TITLE: The Effects of Vitamin D on Orthodontic Tooth Movement    
 
INVESTIGATOR: Nada Tashkandi 
 
This consent form may contain words that you do not understand.  Please ask the study doctor or the 
study staff to explain any words or information that you do not clearly understand.  You may take 
home an unsigned copy of this consent form to think about or discuss with family or friends before 
making your decision. 
 
PURPOSE OF THE STUDY: 
The purpose of this research study is to measure the effects of Vitamin D levels on the rate of 
Orthodontic tooth movement. We think that hypothesized levels of vitamin D in your child’s body 
will be correlated with how his/her teeth move when they have braces on and that that will affect 
the length of treatment. 
 
DESCRIPTION OF THE STUDY 
You will be one of approximately 128 subjects asked to participate in this study. Participating in 
this study will mean that your child will be required to spit into a glass tube for each of your first 
6 routine adjustment appointments after the braces are on. We will measure the level of vitamin D 
in his/her saliva to compare with the speed of your orthodontic treatment. They will also have an 
impression of your upper and lower teeth made after 6 months (at the end of the study period).  
This impression will be done for research purposes only. No other changes will be made from your 
normal orthodontic treatment than if you had not participated in the study.  
 
RISKS AND DISCOMFORTS 
The only discomfort will be in collecting the saliva into the tube. S/he will be given ample time to 
allow the saliva to pool into your mouth and dribble it into the tube. The impressions taken will be 
the same as the ones taken in the initial records appointment. 
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BENEFITS 
Your participation into this study will not affect your orthodontic treatment in any way (neither 
benefit nor worsen). However, it will help in assessing the effects of vitamin D levels on tooth 
movement which will give us a better understanding into how teeth move. 
 
COSTS 
There are no charges for the study visits and they will be taking up 5-10 minutes of your normal 
orthodontic appointment. You will not be reimbursed for participation in this study. 
 
AUTHORIZATION TO USE AND DISCLOSE INFORMATION FOR RESEARCH PUR-
POSES  
Federal regulations give you certain rights related to your health information.  These include the 
right to know who will be able to get the information and why they may be able to get it.  The 
study doctor must get your authorization (permission) to use or give out any health information 
that might identify you.  
 
CONFIDENTIALITY  
Each participant will be given a code and all samples and data will be labeled with this code. Nobody 
other than the PI will be able to identify you with this code. Only the PI will have the master code and 
will keep it in a locked cabinet. Absolute confidentiality cannot be guaranteed because of the need to 
give information to other parties.  The results of this research study may be presented at meetings or 
in publications.  Your identity will not be disclosed in those presentations. 
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VOLUNTARY PARTICIPATION AND WITHDRAWAL 
The language below refers to the information we will use from your child’s medical record. 
 
Use and Disclosure of Your Health Information 
  
Boston Medical Center wants to use and/or share your health information as part of this research 
study. The law requires Boston Medical Center to get your authorization (permission) to do so.   
  
Health information that might be used or given out during this research includes: 
• Information from your hospital or office health records at Boston Medical Center or else-
where. This applies to information that is reasonably related to the aims, conduct, and 
oversight of the research study. If health information is needed from your doctors or hos-
pitals outside of Boston Medical Center, you will be asked to give permission for these 
records to be sent to the researcher. 
• New health information from tests, procedures, visits, interviews, or forms filled out as 
part of this research study. 
The reasons that your health information might be used or given out to others are: 
• To do the research described here 
• To make sure we do the research according to certain standards set by ethics, law, and 
quality groups or otherwise as required by law 
The people and groups that may use or give out your health information are: 
• Researchers involved in this research study from Boston Medical Center 
• Researchers from other institutions or organizations that are involved in this research 
study 
• Other people at Boston Medical Center who may need to access your health information 
to do their jobs such as for treatment, research administration, payment, billing, or health 
care operations 
• People or groups that the researchers use to help conduct the study or to provide over-
sight for the study 
• The Institutional Review Board that oversees the research and other people or groups that 
are part of the Human Research Protection Program that oversees the research 
• Research monitors, reviewers, or accreditation agencies and other people or groups that 
oversee research information and the safety of the study 
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Some people or groups who get your health information might not be obligated to follow the 
same privacy laws that we follow. We ask anyone who gets your health information from us to 
protect the privacy of your information. However, after your information has been shared with 
others, we cannot promise that it will be kept private. 
  
The time period for using or giving out your health information: 
• Because research is an ongoing process, we cannot give you an exact date when we will 
either destroy or stop using or sharing your health information. 
Your privacy rights are: 
• You have the right not to sign this form that allows us to use and give out your health in-
formation for research. If you do not sign this form, you cannot be in the research. This is 
because we need to use the health information to do the research. Your decision not to 
sign the form will not affect any treatment, health care, enrollment in health plans, or eli-
gibility for benefits. 
• You have the right to withdraw your permission to use or share your health information 
in this research study. If you want to withdraw your permission, you must write a letter to 
the Principal Investigator at the address listed on the first page of this form. If you with-
draw your permission, you will not be able to take back information that has already been 
used or shared with others. This includes information used or shared to do the research 
study or to be sure the research is safe and of high quality. If you withdraw your permis-
sion, you cannot continue to be in the study. 
• You have the right to see and get a copy of your health information from the Principal In-
vestigator that is used or shared for research.  
 
The results of this research study may be published in a medical book or journal, or used to teach 
others. However, your name or other identifying information will not be used for these purposes 
without your specific permission.  
 
Taking part in this study is voluntary. You have the right to refuse to take part in this study. If you 
decide to be in the study and then change your mind, you can withdraw from the research. Your 
participation is completely up to you. Your decision will not affect your being able to get health 
care at this institution or payment for your health care. It will not affect your enrollment in any 
health plan or benefits you can get.  
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If you choose to take part, you have the right to stop at any time. If there are any new findings 
during the study that may affect whether you want to continue to take part, you will be told about 
them as soon as possible. 
 
The investigator may decide to discontinue your participation without your permission because 
he/she may decide that staying in the study will be bad for you, or the sponsor may stop the study. 
Do not sign this consent form unless you have had a chance to ask questions and have received 
satisfactory answers to all of your questions. You will be given a copy of this consent form to keep. 
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CONSENT 
I have read the information in this consent form (or it has been read to me).  All my questions about 
the study and my participation in it have been answered.  I freely consent to participate in this research 
study. 
 
The study has been fully described to my child in a manner that is understandable to him/her. My 
child has provided assent to participate in this study by allowing us to view his/her medical records 
 
By signing this consent form I have not waived any of the legal rights which I otherwise would have 
as a subject in a research study. 
 
You may contact the PI with any questions or concerns at nadatash@bu.edu  
 
CONSENT SIGNATURE: 
 
________________________________________ __________________ 
Signature and Printed Name of Parent Date 
 
________________________________________ 
Printed Name of Subject 
 
 
________________________________________ 
Signature of PI 
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Protocols 
ALP (ab83369) from Abcam 
1- Reaction wells set up: 
a. Standard wells = 120 μL standard dilutions. 
b. Sample wells = 2-80 μL samples (adjust volume to 80 μL/well with Assay Buffer). 
c. Sample Background Control wells (for colored samples only) = 2-80 μL samples (ad-
just volume to 80 μL/well with Assay Buffer). 
2- ALP Reaction: 
a. Add 20 μL Stop Solution to Sample Background Control wells to terminate ALP ac-
tivity in these samples. Mix well by pipetting up and down. 
b. Add 50 μL of 5 mM pNPP Solution to each well containing Sample and Background 
Sample Controls. Do not add solution to Standard wells. 
c. Add 10 μL of ALP enzyme solution to each pNPP Standard well. Mix by pipetting up 
and down. 
d. Incubate plate at 25°C for 60 minutes protected from light. The enzyme will convert 
pNPP substrate to an equal amount of colored p-Nitrophenol (pNP). 
e. Stop reaction in Sample wells and Standard wells by adding 20 μL Stop Solution. 
3- Measurement: 
a. Gently shake the plate. 
b. Measure output at OD 405 nm on a microplate reader. 
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VitDBP (CAT. # HCCBP2MAG-58K) from EMD Millipore 
1- Add 200 μL of Assay Buffer for Blocking (L-AB) into each well of the plate. Seal and 
mix on a plate shaker for 30 minutes at room temperature (20-25°C).  
2- Decant Assay Buffer for Blocking (L-AB) and remove the residual amount from all wells 
by inverting the plate and tapping it smartly onto absorbent towels several times.  
3- Add 25 μL of Assay Buffer (L-AB4) to the Background and sample wells.  
4- Add 25 μL of each Standard or Control into the appropriate wells.  
5- Add 25 μL of appropriate matrix to Background, Standard and Control wells. When as-
saying serum or plasma, use the Assay Buffer (L-AB4) provided in the kit. When assaying 
tissue culture or other supernatant, use proper control culture medium as the matrix solu-
tion.  
6- Add 25 μL of diluted sample into the appropriate wells. When assaying serum or plasma, 
use the Assay Buffer (L-AB4) provided in the kit to dilute the sample. When assaying 
tissue culture or other supernatant, use proper control culture medium as the diluent.  
7- Vortex Mixing Bottle and add 25 μL of the Mixed Beads to each well. (Note: During 
addition of Beads, shake bead bottle intermittently to avoid settling.) 
8- Seal the plate with a plate sealer. Wrap the plate with foil and incubate with agitation on a 
plate shaker overnight (16-18 hr.) at 4°C  
9- Gently remove well contents and wash plate 3 times following instructions listed in the 
plate washing section.  
10- Add 25 μL of Detection Antibodies into each well.  
11- Seal, cover with foil, and incubate with agitation on a plate shaker for 1 hour at room 
temperature (20-25°C).  
12- Add 25 μL Streptavidin-Phycoerythrin to each well containing the 25 μL of Detection 
Antibodies.  
13- Seal, cover with foil and incubate with agitation on a plate shaker for 30 minutes at room 
temperature (20-25°C).  
14- Gently remove well contents and wash plate 3 times following instructions listed in the 
plate washing section.  
15- Add 100 μL of Sheath Fluid (or Drive Fluid if using MAGPIX) to all wells. Re-suspend 
the beads on a plate shaker for 5 minutes.  
16- Run plate on Luminex® 200™, HTS, FLEXMAP 3D® or MAGPIX® with xPONENT® 
software.  
17- Save and analyze the Median Fluorescent Intensity (MFI) data using a 5-parameter logistic 
or spline curve-fitting method for calculating analyte concentrations in samples. (Note: 
Multiply the calculated concentration of the samples by the dilution factor, which is 
10000.)  
 
 PLATE WASHING  
1.) Solid Plate  
If using a solid plate, use either a handheld magnet or magnetic plate washer.  
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A.) Handheld magnet (EMD Millipore Catalog #40-285) - Rest plate on magnet for 60 seconds 
to allow complete settling of magnetic beads. Remove well contents by gently decanting the plate 
in an appropriate waste receptacle and gently tapping on absorbent pads to remove residual liquid. 
Wash plate with 200 μL of Wash Buffer by removing plate from magnet, adding Wash Buffer, 
shaking for 30 seconds, reattaching to magnet, letting beads settle for 60 seconds and removing 
well contents as previously described after each wash. Repeat wash steps as recommended in As-
say Procedure.  
B.) Magnetic plate washer (EMD Millipore Catalog #40-094, #40-095, #40-096 and #40-097) - 
Please refer to specific automatic plate washer manual for appropriate equipment settings. Please 
note that after the final aspiration, there will be approximately 25 μL of residual wash buffer in 
each well. This is expected when using the BioTek® plate washer and this volume does not need 
to be aspirated from the plate.  
If using an automatic plate washer other than BioTek® 405 LS or 405 TS, please refer to the 
manufacturer’s recommendations for programming instructions.  
2.) Filter Plate (EMD Millipore Catalog #MX-PLATE)  
If using a filter plate, use a vacuum filtration manifold to remove well contents. Wash plate with 
200 μL/well of Wash Buffer, removing Wash Buffer by vacuum filtration after each wash. Repeat 
wash steps as recommended in the Assay Procedure.  
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Osteoblast Isolation 
Before procedure 
1- Prepare solution A 
a. 137 mM NaCl (8g/L) 
b. 2.7 mM KCl (201 mg/L) 
c. 3mM NaH2PO4 x H2O (414 mg/L) 
d. 1L dH2O 
e. Adjust pH=7.2 
2- Prepare solution B 
a. 4 mM NaEDTA (0.74g/500mL Solution A) 
b. adjust pH=7.2 
3- Filter solution A and B 
4- Prepare solution C 
a. It should be prepared fresh (on the same day, just before use) 
b. Worthington Collagenase Type 2 (180 μ/mL) in Solution A 
c. 40 mL/L 
d. Keep on ice and heat to 370C for 1 min just before use 
The procedure 
1- 2-4 day old mice, sterilized surgical procedure, 6 well plate on ice with one well 70% 
Ethanol 2mL and three wells PBS + 1% FBS 
2- Euthanize pups by Co2 then decapitation 
3- Spray the pup with ethanol in hood 
4- Remove skin from skull 
5- Cut around the sutures to remove the frontal and parietal bones 
6- Remove all remnants of soft tissue and sutures around the calvarial bones 
7- Wash in ethanol then PBS/FBS 3 times. Keep in last well on ice.  
In the lab 
1- Move calvaria from PBS/FBS to 25mL flask 
2- Wash calvaria with 5mL Solution A then suction 
3- Incubate calvaria and shake for 10 min at 370C at 100rpm as follows 
a. 5 mL solution B x 3 times and discard 
b. 5 mL solution C x 2 times and discard 
c. 5 mL solution C x 5 times and collect supernatant 
4- Centrifuge supernatants at 300g x 5 min at 240C 
5- Aspire supernatant andRe-suspend in alpha-MEM and move to 75 cm2 flask with 10% FBS 
and 1% antibiotic (p/s) 
6- Incubate in CO2 at 370C 
7- Change media every 3 days 
8- View under microscope until reaching 90% confluence 
9- Passage into plates for treatment 
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Detachment of osteoblasts 
1- Aspirate media from flasks 
2- Add 3mL Trypsin/EDTA with gentle tapping 
3- Incubate for 3 min at 370C in CO2 
4- View under microscope to evaluate detachment 
5- Add 9 mL of alpha-MEM/FBS/PBS 
6- Centrifuge then aspirate media 
7- Count cells under microscope 
8- Calculate number of cells per well needed and plate 
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ELISA (Quantikine ELISA Mouse Osteoprotegerin/TNFRSF11B Immunoassay (Cat. # 
MOP00) and Mouse TRANCE/RANK L/ TNFSF11 (Cat. # MTR00)) from R&D systems 
Plate Preparation 
1- Dilute the Capture Antibody to the working concentration in PBS without carrier protein. 
Immediately coat a 96-well microplate with 100 μl per well of the diluted Capture antibody. 
Seal the plate and incubate overnight at room temperature 
2- Aspirate each well and wash with Wash Buffer, repeating the process two times for a total 
of three washes. Wash by filling each well with Wash Buffer (400 μl) using a squirt bottle, 
manifold dispenser or an autowash. Complete removal of liquid at each step is essential for 
good performance. After the last wash, remove any remaining Wash Buffer by aspirating 
or by inverting the plate and blotting it against clean paper towels. 
3- Block plates by adding 300 μl of Reagent Diluent to each ell. Incubate at room temperature 
for a minimum of 1 hour. 
4- Repeat the aspiration/wash step as in step 2. The plates are now ready for sample addition 
Assay procedure 
5- Add 100 μl of sample or standards in Reagent Diluent or an appropriate diluent, per well. 
Cover with an adhesive strip and incubate 2 hours at room temperature. 
6- Repeat the aspiration/wash step as in step 2 of plate preparation 
7- Ass 100 μl of the Detection Antibody, diluted in Reagent Diluent to each well. Cover with 
a new adhesive strip and incubate 2 hours at room temperature. 
8- Repeat the aspiration/wash step as in step 2 of plate preparation 
9- Add 100 μl of the working dilution of Streptavidin-HRP to each well. Cover the plate and 
incubate for 20 min at room temperature. Avoid placing the plate in direct light. 
10- Repeat the aspiration/wash step as in step 2 of plate preparation 
11- Add 100 μl of Substrate Solution to each well. Incubate for 20 min at room temper-
ature. Avoid placing the plate in direct light. 
12- Add 50 μl of Stop Solution to each well. Gently tap the plate to ensure thorough 
mixing. 
13- Determine the optical density of each well immediately, using a microplate reader 
set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength 
correction is not available, subtract readings at 540 or 570 nm from the readings at 450 nm. 
The subtraction will correct for optical imperfections in the plate. Readings made at 450 
nm without correction may be higher and less accurate. 
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RNA Extraction (RNeasy kit) from Qiagen 
Procedure 
1- Harvest cells: Cells grown in a monolayer (do not use more than 1 x 107 cells): Cells can 
be either lysed directly in the cell-culture vessel (up to 10 cm diameter) or trypsinized and 
collected as a cell pellet prior to lysis. Cells grown in cell-culture flasks should always be 
trypsinized. 
To lyse cells directly: 
Determine the number of cells. Completely aspirate the cell-culture medium, and proceed 
immediately to step 2. 
Note: Incomplete removal of cell-culture medium will inhibit lysis and dilute the lysate, 
affecting the conditions for binding of RNA to the RNeasy membrane. Both effects may 
reduce RNA yield. 
2- Disrupt the cells by adding Buffer RLT. 
For direct lysis of cells grown in a monolayer, add the appropriate volume of Buffer RLT 
to the cell-culture dish. Collect the lysate with a rubber policeman. 
Pipet the lysate into a microcentrifuge tube (not supplied). Vortex or pipet to mix, and 
ensure that no cell clumps are visible before proceeding to step 3. 
3- Homogenize the lysate. 
If processing ≤1 x 105 cells, homogenize by vortexing for 1 min. After homogenization, 
proceed to step 4. 
Note: Incomplete homogenization leads to significantly reduced RNA yields and can cause 
clogging of the RNeasy spin column. Homogenization with a rotor–stator or QIAshredder 
homogenizer generally results in higher RNA yields than with a syringe and needle. 
Pipet the lysate directly into a QIAshredder spin column placed in a 2 ml collection tube, 
and centrifuge for 2 min at full speed. Proceed to step 4. 
4- Add 1 volume of 70% ethanol to the homogenized lysate, and mix well by pipetting. Do 
not centrifuge. 
Note: The volume of lysate may be less than 350 μl or 600 μl due to loss during homoge-
nization. 
Note: When purifying RNA from certain cell lines, precipitates may be visible after addi-
tion of ethanol. This does not affect the procedure. 
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5- Transfer up to 700 μl of the sample, including any precipitate that may have 
formed, to an RNeasy spin column placed in a 2 ml collection tube (supplied). Close the 
lid gently, and centrifuge for 15 s at ≥8000 x g (≥10,000 rpm). Discard the flow-through. 
Reuse the collection tube in step 6. 
6- Add 700 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 s at ≥8000 x g (≥10,000 rpm) to wash the spin column 
membrane. Discard the flow-through. Reuse the collection tube in step 7. 
Note: After centrifugation, carefully remove the RNeasy spin column from the collection 
tube so that the column does not contact the flow-through. Be sure to empty the collection 
tube completely. 
7- Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 s at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. Discard 
the flow-through. Reuse the collection tube in step 8. 
Note: Buffer RPE is supplied as a concentrate. Ensure that ethanol is added to 
Buffer RPE before use. 
8- Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 2min at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. The 
long centrifugation dries the spin column membrane, ensuring that no ethanol is carried 
over during RNA elution. Residual ethanol may interfere with downstream reactions. 
Note: After centrifugation, carefully remove the RNeasy spin column from the collection 
tube so that the column does not contact the flow-through. Otherwise, carryover of ethanol 
will occur. 
9- Optional: Place the RNeasy spin column in a new 2 ml collection tube (supplied), and 
discard the old collection tube with the flow-through. Close the lid gently, and centrifuge 
at full speed for 1 min. Perform this step to eliminate any possible carryover of Buffer RPE, 
or if residual flow-through remains on the outside of the RNeasy spin column after step 8. 
10- Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). Add 30–50 μl 
RNase-free water directly to the spin column membrane. Close the lid gently, and centri-
fuge for 1 min at ≥8000 x g (≥10,000 rpm) to elute the RNA. 
11- If the expected RNA yield is >30 μg, repeat step 10 using another 30–50 μl RNase free 
water, or using the eluate from step 10 (if high RNA concentration is required). Reuse the 
collection tube from step 10  
118 
 
cDNA Extraction 
 
1- Prepare RT and No RT control reaction mixes (on ice) 
Component RT reaction No RT Control reac-
tion 
SuperScript IV VILO Master Mix 4uL - 
SuperScript IV VILO No RT Control - 4uL 
Template RNA 1pg to 2.4ug total RNA) varies varies 
Nuclease-free water to 20uL to 20uL 
 
2- Anneal primers: gently mix and incubate at 250C for 10 min  
3- Reverse transcribe RNA: incubate at 500C for 10 min 
4- Inactivate enzyme: incubate at 850C for 5 min  
5- qPCR amplification: use diluted or undiluted cDNA for qPCR or store at -200C for up to 
one week or -700C for long term storage  
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Cell lysis by CellLytic M (Cat. #C2978) from Sigma 
1- Was cells and treat with CellLytic M. 
a. For adherent cells: Remove the growth medium from the cells to be assayed. 
Rinse the cells once with DPBS being careful not to dislodge any of the cells and 
discard DPBS. Add appropriate volume of CellLytic M reagent. 
2- Incubate the cells for 15 min on a shaker 
3- Collect lysed cells 
a. For adherent cells: Remove cells from plates (cell scraping might increase total 
protein yield) 
4- Centrifuge the lysed cells for 15 min at 12,000 -20,000 x g to pellet the cellular debris 
5- Remove the protein containing supernatant to a chilled test tube 
Note: Lysate preservation requires low temperatures. Therefore, for long term storage it 
is recommended to store lysate at -700C. 
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BCA protein concentration 
1- Pipette 25 μl each standard or protein sample replicate into individual wells of a 96-well 
plate 
2- Add 200 μl BCA working reagent to each well. Mix on plate shaker for 30 seconds. 
Cover plate. 
3- Standard assay: incubate reaction at 370C for 30 min or at room temperature for 2-16 
hrs. 
Enhanced assay: incubate reactions at 600C for 15 min 
4- Cool plate to room temperature 
5- Measure absorbance at 562 nm on a plate reader 
Note: if the plate reader does not have a 562 nm filter, wavelengths from 540-590 nm 
have been used successfully 
6- To obtain corrected absorbance, subtract the absorbance of the blank standard from the 
absorbance measurement or all other standard and protein samples 
7- Plot the corrected absorbance versus the known mass of the BSA standards to generate 
the standard curve. 
Note: if a curve fitting algorithm associated with the microplate reader is used for prepar-
ing the standard curve, a four parametric (quadratic) or best-fit curve will provide the 
most accurate results 
8- Using the standard curve, interpolate the recorded corrected absorbance reading for the 
samples assayed which fall within the liner range of the standard curve 
9- Calculate the amount of protein present in the original sample by correcting for dilution 
and sample volume 
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Western Blot 
1- Wash cells 1x with DPBS 
2- Collect cells and follow Lysis buffer specific protocol, centrifuge and use supernatant 
3- Perform BCA or Bradford assay to determine protein concentration. Freeze samples at -20 
or -800C for later use or continue. 
4- Thaw samples completely and mix well. Centrifuge at 10,000 x g for 8 min to pellet debris. 
5- Calculate amount/volume of sample needed. Always load equal amounts of sample, vol-
umes may vary or bring to equal volumes with PBS. 
6- LDS buffer to calculation. 
7- Boil for 5-8min at 1000C in boiling water bath. 
8- Let cool and centrifuge at 10,000 x g for 1 min 
9- Load all sample to gel. 
10- Remove green casting frame, place gels in inner electrophoresis chamber, wells facing in-
ward. Squeeze gel molds together and lock into place. Put inner chamber into running tank. 
11- Fill inner chamber with running buffer to just overflow it. 
12- Pour out some buffer from inner chamber until level is about halfway filling the gel wells. 
13- Use 1ml pipette to clean each well and remove excess Acrylamide, using 800ul buffer/bub-
bles. 
14- Refill inner chamber with running buffer (if leaky dump out all running buffer, remove 
inner chamber, re-lock the gels into place, and try again) 
15- Load samples into wells (always load 10ul of ladder at one or both ends of the gel) 
16- Add more running buffer in outer chamber to be around 2 inches from the bottom. 
17- Put lid in place, red-red and black-black. Run gel at 80-85V for 2 hrs or 100V for 1 hr. 
Transfer 
18- Soak two filter papers and two foam pads in Blotting buffer (BB) for 10 min 
19- Fill one tray with methanol to activate membrane (1min) 
20- Fill second tray with BB to equilibrate gel, gently open glass gel frame ad remove top glass 
pane. Cut off gel comb and any excess gel. Gently rock the gel off the glass plate into BB 
to equilibrate (5-10 min). 
21- Dump methanol from membrane and pour in BB (it will float so keep it wet) 
22- Dump gel’s BB into the transfer apparatus and refill with new BB. 
23- Slide filter paper under the gel in the tray in BB, center the gel on top of filter paper. 
24- On the BLACK side of the clamp case, layer as follows: 
a. Bottom: 1 foam pad 
b. Filter paper with gel on top 
c. PVDF membrane (cut with razor to just cover the gel, ensure no bubbles and keep 
wet with BB) 
d. Filter paper (do NOT move once laid down) 
e. Top: 1 foam pad 
25- Close case, squeeze and keep pressure in the center of the case, slide lock over. 
26- Insert into inner chamber with black side to black side. 
27- Fill outer tank with BB (do NOT pour over clamp/case) until level with top edge of outer 
tank. 
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28- Run at 40C with ice pack inside chamber at constant mAmps at 66mA overnight  
29- Remove membrane from transfer apparatus. Ensure all of the visible ladder has been trans-
ferred from the gel to the membrane. Handle the membrane with forceps gently. 
30- Discard BB in hazardous waste container 
Blocking 
31- Use milk or BSA depending on the primary antibody incubation buffer recommendation 
32- Prepare 10ml block buffer per membrane (5% milk or BSA): 20ml TBS-T + 1g dried milk 
or BSA 
33- Remove membrane, place in tray with TBS-T for 5 min then replace with blocking buffer 
for 1-2 hours at room temperature. 
Primary Antibody 
34- Prepare 10 ml of 5% milk or BSA per membrane depending on antibody manufacturer’s 
datasheet with appropriate concentration of antibody 
35- Make pouches for membrane, seal three sides with heat sealer 
36- Add antibody/buffer (10ml per pouch), seal and shake overnight at 40C or 2 hr at RT 
Secondary Antibody 
37- Remove from pouches and wash 3 x 10 min in TBS-T 
38- Make 10ml 5% milk per membrane with appropriate concentration of secondary antibody. 
39- Replace TBS-T with antibody/buffer and shake for 1-2 hrs at room temperature. 
Developing 
Stripping/Reprobing 
40- Rinse membranes in TBS-T for 3 x 5min 
41- Place in pouch and add 10ml Strip Buffer and incubate at 370C in shaker for 20 min. 
42- Discard strip buffer in Hazardous waste container 
43- Rinse 3 x 10 min in TBS-T 
44- Reblock for 1 hour at room temperature in 5% milk or BSA (antibody dependent) 
45- Continue with new target antibody as above. 
To save membrane 
46- After transferring, wash membranes in ultrapure water 3 x 10min 
47- Dry membrane completely on filter paper and place in pouch 
48- When ready to use 
a. Activate membrane in methanol for 2 min 
b. Wash in ultrapure water 3 x 10min 
c. Block in 5% milk or BSA for 1-2 hrs at room temperature 
d. Continue with WB procedures 
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